Title of Invention	AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES
Abstract	The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses.

Full Text

The present invention relates to novel compounds which are glycine transporter inhibitors and as such effective in the treatment of disorders in the CKS, such as schizoplirenia. Background of the invention Glutamic acid is the major excitatory amino acid in the mammalian central nervous system (CNS), and acts through two classes of receptors, the ionotropic and metabotrobic receptors, respectively. The ionotropic glutamate receptors are divided into three subtypes based on the affinities of agonists for these receptors, namely A^-methyl-D-aspartate (NMDA), (i?^-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propaiioic acid (AMP A) and kainic acid (or kainate) receptors. The NMDA receptor contains binding sites for modulatory compounds such as glycine ^d polyamines. Binding of glycine to its receptor enhances the NMDA receptor activation. Such NMDA receptor activation may be beneficial for the treatment of schizoplirenia and other diseases linlced to NMDA receptor dysfunction. An activation can be achieved by an inhibitor of the glycine transporter. Molecular cloning has revealed the existence of two types of glycine transporters, GlyT-1 and GlyT-2, wherein GlyT-1 can be further subdivided mto GlyT-la, GlyT-lb andGlyT-lc. The NMDA receptor is blocked by compounds such as phencyclidine which induce a psychotic state which resembles schizophrenia. Likewise, the NMDA antagonists, such as ketamine, induce negative and cognitive symptoms similar to schizophrenia. This indicates that NMDA receptor dysflmction is involved in the pathophysiology of schizophrenia. The NMDA receptor has been associated with a number of diseases, such as pain (YdkshPain 1989, 37,111-123), spasticity, myuoclonus and epilepsy (Truong et. al. Movement Disorders 1988, 3, 77-87), learning and memory (Rison et. al. Newosci. Biobehav. Rev. 1995, 19, 533-552), post-traumatic stress disorder (abbreviated: PTSD) (Heresco-ie\y et. al. The InternatianalJournal ofNeuropsychopharmacolog)>, 2002, 5:301-307, entitled; ^Tilot-controlled trial of D-cycloserine for the t'eatment of post-traumatic stress disorder"). Glycine transporter antagonists or inhibitors are believed to be highly beneficial in the treatment of schizophi-enia (Javitt WO 97/20533). Glycine transport antagonists or inhibitors could be useful for the treatment of both the positive and the negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are dhninished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by irmer or outer influence, such as trauma to fhe head or stroke. Likewise, convulsive disorders such as epilepsy, spasticity or myoclonus may benefit from glycine transporter antagonists. Cluiical trials with glycine have been reported, Javitt et. al. Am. J. Psychiatry 1994, 151, 1234-1236 and Leidennan et. al. Biol. Psychiatry 1996, 39, 213-215, The treatment with high-dose glycine is reported to improve fhe symptoms of schizopiirema. Thare is a need for more efficient compounds foi the treatment of NMDA associated diseases. Summary of the invention The present iuvention relates to compounds of formula 1 which, are potent inhibiters of the glycine transport. In one aspect, the present invention relates to a compound of the general formula I wherein tlie substituents ai-e as defined below. FmHiermore, the invention provides a compound of formula I as above for use as a medicament. Moreover, the invention provides a pharmaceutical composition comprising a compound of formula I as above or a pharmaceutically acceptable salt thereof, e.g. a phannaceuticaliy acceptable acid addition salt thereof, and at least one pharmaceutically acceptable carrier or diluent. The invention also provides the use of a compound of formula I as above or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of diseases selected from the group consisting of schizophi-enia, including both the positive and the negative symptoms of schizoplirenia and other psychoses, and in the improvement of cognition in conditions where tlae cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive disorders such as epilepsy, spasticity or myoclonus. The invention also provides the use of a compound of formula I as above or a ) pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of post-traumatic stress disorder. The invention also provides a method for the treatment of diseases selected from the group consisting of schizophi'enia, including both the positive and the negative svinpioms of scliizophi-enia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive disorders such as epilepsy, spasticit>' or myoclonus in a living animal body, including a limnan, comprising administering a therapeutically effective amount of a compound of fonnula I as above or a phannaceutically acceptable acid addition salt thereof The invention also provides a method for the treatment of post-tramnatic stress disorder in a living animal body, including a himian, comprising administering a therapeutically effective amount of a compoimd of fonnula I as above or a pharmaceutically acceptable acid addition salt thereof. Definitions The teim "halogen" means fluoro, chloro, bromo or iodo. The expression "Ci-6-alk(enyyn)yI" means a Ci.6-allcyl, C2-6-alkenyl or a Cz-ralkynyi group. The expression "C3.8-cycloalk(en)yl" means a Cs-g-cycloaJkyI- or cycloaUcenyl group. The term "Ci-g alkyl" refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, including but not limited to methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl. The term "C2-6 allcenyl" designate such groups having from two to six carbon atoms, including one double bond, including but not limited to ethenyl, propenyl, and butenyl. The term "C2-6 aEcynyl" designate such groups having from two to six carbon atoms, including one triple bond, including but not hmited to eth^yl, propynyl and butynyl. The term "Cj-g cycloalkv'l" designates a monocyclic or bicyclic carbocycle having tlii-ee to eig]:t C-atoms, including but not limited to cyclopropyl, cyclopentj^l, cyclohexyl, elc. The tenn "Cj-fi cycloalkenyl" designates a monocyclic or bicycUc carbocycle having three to eight C-aioms and including one double bond. '.n the term "C3-g--cycloalk(en)yl-Ci-6-aik(eii/yn)yr', C3-s-cycloallc(en)yl and d-e-iLk(en/yii)yl are as defined above. The terms "C,.e-alk(en/yii)yloxy", "C-G all:{en/yn)ylsulfauyl", "hydroxy-C,.6-ELllc(en/yn)yl", "halo-Ci.6-alk(en/yn)yI", "halo-Ci.6-alk(en/yn)yloxy", "CL^-alk(en/yn)ylsulfonyl" etc. designate such groups in which the Ci-6-alk(en/yii)yl is as defined above, and "halo" means halogen. The term "C|.c alk(en/yn)ylsulfanyl-C]-6-alk(enyyn)yl" designate such group in which the Ci-6 allc(en/yn)ylsulfauyl and Ci-6-alfc(en/yn)yl are as defined above. As used herein, the term "Ci-s-alk(en/yn)yIoxycarbonyr' refers to groups of the formula Ci.6-allc(en/yn)yl-0-C0-, wherein Ci.fi-alk{en/yn)yl are as defined above. As used herein, the term "acyl" refers to formyl, C]-6-alk(en/yn)ylcarbonyl, arylcarbonyl, aryl-Ci.6-alk(en/yn)yIcarbonyl, C3-E-cycloalk(en)ylcarbonyl or a C^s-cycloalk(en)yl-Ci.6-alk(en/yn)yl-carbonyl group, wherein aryl is defined below. Tlie term "together with the nitrogen form a saturated 3-7-membered heterocyclic ring" as used herehi refers to saturated ring systems having from 2 to 6 carbon atoms and one nitrogen, such as 1-pyrroHdinyl, 1-piperidinyl or 1-azepinyl, all of which may be fiirther substituted with Ci.fi-alkyl. The term "together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S, or N" as used herein refers to saturated or unsaturated ring systems having from 2 to 6 carbon atoms and one nitrogen, or 2 to 5 carbon atoms and two nitrogens, one nitrogen and one oxygen, or one nitrogen and one sulphur, such as l-morpholinyl, 1-piperidinyl, 1-pyrroHdinyl, ]-az,epinyl, 1-piperaziiiyl, 1-homopiperazinyl, 1-imidazolyl, l-pyrrolyl or 1-pyi-azolyL all of which may be further substituted with Ci-e-allcyl. The term "ar>d" refers to cai-bocyclic, aromatic systems, such as phenyl and naphthyl. The term "monocyclic heteroaryl" refers to 5- to 6- membered aromatic systems containing 1 to 5 carbon atoms and one or more heteroatoms selected from O', S or N, such as 5-membered monocyclic rings such as oxathiazoles, dioxazoles, dithiazoles, oxadiazoies, thiadiazoles, triazoles, isoxazoles, oxazoles, isothiazoles, thiazoles, imidazoles, pyrazoles, pyrroles, iuran(s) or thiophene(s), e.g. 3H-l,2,3-oxathiazole, 1,3,2-oxathiazole, 1,3,2-dioxazole, 3/7-1,2,3-dithiazole, 1,3,2-dithiazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, I//-l,2,3-triazole, isoxazole, oxazole, isothiazole, thiazole, lif-imidazole, lj7-pyrazole, liif-pyrrole, furan or thiophene, or 6-membered monocyclic rings such as oxathiazines, dioxazines, dithiazines, oxadiazines, tliiadiazines, triazines, oxazines, thiazines, pyrazines, pyridazines, pyrimidines, oxathiins, dioxins, dithiins, pyridines, pyrans or thiins, e.g. 1,2,3-oxathiaziiie, 1,2,4-oxathiazine, 1,2,5-oxathiazine, 1,4,2-oxathiazine, 1,4,3-oxathiazine, 1,2,3-dioxazine, 1,2,4-dioxazine, 4i7-l,3,2-dioxazine, 1,4,2-dioxaziiie, Zff-l,5,2-dioxazine, 1,2,3-dithiazine, 1,2,4-dithiazine, 4i/-l,3,2-dithiazine, 1,4,2-ditbiazine, 2H-l,5,2-dithiazine, 2i7-l,2,3-oxadiazine, 2ff-I,2,4-oxadia2ine, 2iiM,2,5-oxadiazine, 2i?-l,2,6-oxadiazine, 2H-\,3,4-oxadiazine, 2H-1,2,3-thiadiazine, 2if-l ,2,4-thiadiazine, 2H-1,2,5-thiadiazine, 2iJ-l,2,6-'thiadiazine, 2ff-l,3,4-thiadiazine, 1,2,3-triazine, 1,2,4-triazme, 2^-1,2-oxazine, 2/f-l,3-oxazine, 2H-l,4-oxazine, 2i7-l,2-thiazine, 2H-l,3-thiazine, 2/ir-l,4-thiazine, pyrazine, pyridazine, 1,3-pyrimidine, 4if-l,3-oxathiin, 1,4-oxathiin, 4H'-l,3-dioxin, 1,4-dioxin, 4i:f-l,3-dithiin, 1,4-dithiin, pyridine, 2H-pyran or 2H-thiin, The term "allcali metal" refers to lithium, sodium, potassium and cesium. Deacription of the invention The present invention relates to compounds of formula I which are potent inhibiters of the glycine ti'aiisponer and consequently they are useful in treating diseases associated with NINCDA dysftinction, such as schizophrenia. X is O, S or CR"R'^, wherein R^' and R'^ independently are selected from H or Ci.6 aUcyl; YisOorS: R\ R^, R^ and R"^ are independently selected from hydrogen; halogen; cyano; nitro; C|.6-alk(en/yn)yl; Ci-(5-alk(en/yn)yloxy; Ci.6-allc(en/yn)ylsulfanyi; hydroxy; hydroxy- C|.6-allc(en/yn)yl; halo-Ci.6-alk(en/yn)yl; haio-Ci,5-aik(en/yn)yloxy; C3.8- cyc]oaIk(en)yl; C3-8-cycIoalk(en)yl-Ci.6-alk(en/yn)yl; acyl; C].6- alk(en/yn)yloxycarbonyl; Ci.6-aIk{en/yn)ylsulfonyl; aryl optionaUy substituted with a halogen, cyano, nitro, C|-6-aIk(en/yn)yl, Ci-6-aUc(en/yn)yloxy, C1.6-alk(en/yn)ylsulfanyl, hydi-oxy, hydroxy-Ci.6-aUc(en/yn)yl, halo-CiH5-alk(en/yn)yl, halo-Ci.6-aUc(en/yn)yloxy, C3.B-cycloalk{en)yl, C3-B-cycloalk(en)yl-Ci-6-alk(eii/yn)yl, acyl, Ci.(3-alk(en/yn)yloxycarbonyl or Ci-6-aIk(en/yn)ylsulfonyl; monocyclic heteroary] optionally substituted with a halogen, cyano, nitro, C].6-aUc(en/yn)yl, Ci_6-alk(en/yn)yloxy, Ci.(;-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-Ci-o-alk(en/yn)yl, halo-C!-6-ailc(en/yn)yl, halo-C:-6-a]k(en/yn)yloxy, C3^-cycloallc(en)yl, C3-g-cycloallc(en)yl-Ci-6-anc(en'y]i)yl, acyl, Ci.6-allc(en/yn)yloxycarbonyl or C].6-alk(en/yn)ylsulfonyl; or -NR "'R' wherein R'^ and R"^ independently are selected from hydrogen, Ci-e-allv(en/yn)yl, C-.B-cycloalli:(en)yl, C3.rcycloalk(en)yl-Cu6 alk{en/'yn)yl or ar>'l, or R'^ and R together with the nitrogen fonn a 3-7-membered heterocyclic ring which optionalh- contains one frirther heteroatom selected from 0. S or N; 16 R is aiy! or monocyc)ic heteroaiyl, optionally substituted with a halogen, cyano, nitro, Ci.5-alk(en/yn)yl, Ci-6-allc(en/i'n)yloxy, Ci,6-alk:(eiVyn)ylsulfanyl, hydroxy, hydroxy-C,.6-alk(en'yn)yI, halo-Ci.6-alk(en/yn)yl, halo-Ci.6-alk(en/yn)yloxy, Cs.g-GycloaIlc(en)yl, C3.8-cycloalk(en)yl-Ci.6-alk(en/yia)yl, acyl, Ci-e-allc(eii'yn)yloxycarbonyl, Ci-6-allc{en.'yn)ylsulfon.yl, or-NR^^R^^ wherein R'^ and R independently are selected from hydrogen, Ci.6-alk(en/yn)yl, C3.g-cycloalk(en)yl, C3-g-cycloalk{en)yl-C]-6 alk(en/yn)yl or aryl, or R'^ and R^^ together with the nifrogen form a 3-7-membered heterocyclic ring which optionally contains one fiiither heteroatoffi selected from O, S or N; R** is selected from H, Ci.6-allc(en/yn)yl, Ci-e-alk(en/yn)yloxy, Ci-g-alk(en/yn)ylsulfanyl, or C3-g-cycloaIk(6n)yl, provided that when R is selected from C]„6-allc{en/yn)yloxy, or Ci.6-alk(en/yn)ylsulfanyl then X is CR^'R^^, wherein R*' and R'^ independently are selected from H or C).G alkyl; R'and R^ are independently selected from H, Ci-(3-alk(en/yn)yl or C3,E-cycloalk(en)yl; R^ and R^' are independently selected from H, Ci.6-alk(en/yn)yl, hydroxy-Ci.6-alk(en/yn)yl, CI-Q aUc(en/yn)ylsiilfanyl-Ci-6-alk(en/yn)yl or C3-8-cycloalk(en)yl; or R^ and R^ together with the nifrogen form a saturated 3-7 membered heterocyclic ring, and R' is selected from H, CK6-alk(enyyn)yl, or C3,8-cycloalk(en)yl, and R^ and R^' are independently selected from H, Ci.6-alk(en/yn)yl, hydroxy-Ci.6-alk(en/yn)yl, Ci-e alk(en/yn)ylsulfanyl-Ci.6-aIk(en/yn)yl, or C3.B-cycloallc(en)yl; or R^ and R^ together with the nifrogen form a saturated 3-7 membered heterocyclic ring, and R"^ is selected from H, Ci.6-alk(enyyn)yl, Ci-G-alk(en/yn)yloxy, C\.(,-all C]_,6-allc(en'yii)yloxy, or Ci-6-alk(en/yn)ylsulfanyI then X is CR"R'^, wherein R" and R^^ independently ai'e selected from H, or Ci-;^ allcyl, and R^ and R^' are independently selected from H, Ci,e-alk(en/yn)yl liydroxy-Ci.6-alk(en/ynVl C,.^ alk(en/\Ti)ylsulfanyl-Ci.e-alk(en/>Ti)yl or C3-rcycloalk(en)yl; or R^ and R^ together with the nitrogen fomi a saturated 3-7 merafaered heterocyclic ring, and R"^ is selected from H, Ci.6-alk(en/yn)yl, Ci_G-alk{en/yir)yIoxy, Ci-6-alk(en'yn);'lsulfan;'L or C3.E-cyc3oalk(ei:)yl, provided that when R*^ is selected from Ci^6-alk(eii'yn)yloxy, or Ci-6-a!k(en/'yn)ylsulfanyl then X is CR'^R^^, wherein R' and R'^ independently are selected from H or Ci.6 allcj'l, and R' is selected from H, Ci.e-alk(en/yn)yl, or C3.s-cycloallc(6n)yL and R^' is selected fromH, Ci.6-alk(eii/yn)yl, hydroxy-C].6-aIk(en/'yn)yI, Ci-e alk(eiv'yii)yIsuifanyI-Ci-6-aIk(en/yn)yI or C3-E-cycloallc(en)yl; R'° is H, Ci.6-allc(en/yn)yl, aryl, aryl-Ci.6-alk(en/yn)yl, wherein aryl is optionally substituted with a halogen, CF3, OCF3, CN, NO2 or Ci-fi-alk(en/yn)yl; or an allcali metal, such as sodium, potassium or hthium; or a salt thereof, such as a pharmaceutically acceptable salt. In anembodiment of formula I, Xis 0. In another embodiment of formula I, Xis S. In a further embodiment, X is CR'^R'^ wherein R" and R'^ independently are selected from Cue alkyl, such as methyl. In a farther embodiment, X is CHR^', wherein R" is selected from C1.6 alkyl, such as methyl. In a ftirther embodiment, X is CH2. tn a ftirflier embodiment of formula I, Y is 0. In a further embodiment, Y is S. In a further embodiment of formula I, X is O and Y is S. In a further embodiment of formula I, R^ is hydrogen. In a ftirther embodiment, R' is selected from Ci-e-alkyi, such as methyl, ethyl, n-propyl, isopropyl or t-butyl. In a ftirther embodiment, R' is selected from a halogen, such as CI, F, Br or I, e.g. CI. In a ftirther embodiment of formula I, R' is -NR'^R'" wherein R^^ and R"* independently are selected from laydrogen, Ci.6-allc(erL/yn)yi, C3.s-cycloalk(en)yl, C3.g-cycloalk(en)yl-Ci-6alk(eivyn)yIoraryl. In a farther embodiment of formula I, R^ is-NR' R-' wherein R"' and R'"^ together with the nitrogen fomi a 3-7-membered heierocydic ring selected from 1-morpholinyl, 1-piperidinyi, l-p>Trolidinyl, 1-azepinyl, 1-piperazinyL l*homopiperazinyl, l-imidazolyl, l-pyrrolylor 1-pyrazolyl, optionaily substituted with a Ci-6-alkyI. In a further embodiment of formula I, R' is phenyl optionally substituted with a halogen, cyano, nitro, Ci.6-alk(en/yn)yl, Ci-e-alk(eii/yn)yloxy,. Cj.6-allc(en/yn)ylsulfanyl, hydroxy, hydroxy-Cj^-alk(erL'y]i)y], halo-C^6-alk:(en'j'n)yl, halo-Ci_6-aIlc(en/yn)yloxy, C3.8-cycloalk(en)yl, C3-E-cycloallc(en)yl-Ci.6-alk(erL'yn)yl, acyl Ci.e-alk(en/yn)yloxycarbonyl or C|-6-aIk(en,'yn)ylsulfoiiyl, such as phenyl substituted with one or two subtituents, typically one, selected from Ci-6-aIlcyl, or Ci_5-atlcoxy, e.g. methoxy. In a fiu'ther embodiment of formxila I, R is hydrogen. In a further embodiment, R is selected from Ci-a-alkyl, such as methyl, ethyl, n-propyl, isopropyl or t-butyl. In a further embodiment, R^ is selected from a halogen, such as CI, F, Br or I, e.g. CI. In a further embodiment of formula I, R^ is cyano. In a further embodiment of formula I, R^ is -NR'"^R'' wherein R'^ and R'' independently are selected from hydrogen, C|_5-allc(enyyn)yl, C3-B-cycioaIk(en)yl, C3-g-cycloalIc(en)yl-CM5 alk(en/yn)yl or aryl In a further embodiment of foimula I, R^ is -NR'^R'^ wherein R'^ and R"" together with the nifrogen form a 3-7-membered heterocyclic ring selected from 1-morpholinyl, 1-piperidinyl, 1 -p3arolidinyl, 1 -azepinyl, 1 -ptperazinyl, I -homopiperazinyl, 1 -imidazolyl, 1-pyrrolyl or l-pyrazolyl, optionally substituted with a Ci-^-alkyl. In a further embodiment of formula I, R^ is selected from 1-morpholinyl, or 1-piperidinyl. In a further embodiment of formula I, R^ is phenyl. In a further embodiment of formula I, R^ is phenyl substituted with a halogen, cyano, nifro, Ci-6-alk(en/yn)yl, C]_ 6-alk(en/yn)yloxy, Ci^--alk(en/yn)ylsulfanyl, hydroxy, hydroxy-Ci.6-alk(en/yn)yl, halo-Ci-6-allc(en/yn)yl, halo-Ci.6-alk(en/yn)yloxy, C3.8-cycIoalk(en)yl, €3.8-cycioalk(en)yI-Ci.6-allc(en/yn)y!, acyl, Ci.6-alk(en/yn)yIoxycarbonyI or Ci.^-allc(en/yn)ylsulfonyl, such as phenyl substituted witli one or two subtituents, typically one, selected from Cj.6-alky] or Cj-g-alkosy, e.g. methoxy, or one selected from cyano or C].G-allcylsulfonyl, such as methanesulfonyl. In a further embodiment of formula I, R^ is a monocyclic heteroaryl, such as pyrimidinyl. In a further embodiment of formula L R' is hydrogen. In a further embodiment, R"* is selected from Ci-(i-alkyl, such as methyl, ethyl n-propyl, isopropyl or t-butyl. In a fiiither embodiment, R^ is selected from a halogen, such as CI, F, Br or I, e.g. CI In a further embodiment of formula I, R' is -NR'^'R'' wherein R'^ and R'' independently are selected from hydrogen, Ci.G-alk:(en/yn)yl, C3.8-cycIoalk(en)yl, C3-S- cycloalk(en)yl-Ci-6 alk(en'yn)yl or aryl In a further embodiment of formula 1, R^ is - NR'^R^"* wherein R'^ and R'"* togedier witli the uih-ogen form a 3-7-membered heterocyclic ring selected from l-morphoiinyl, 1-piperidinyl, 1-pyrrolidinyl, 1- azepinyl, 1-piperazinjd, l-homopiperazinyl, l-imidazolyl, 1-pyrrolyl or 1-pyi-azolyl, optionally substituted with a Ci-c-alkyl. In a further embodiment of formula I, R^ is phenyl. In a further embodiment of fonnula I, R"' is phen>'l substituted with a halogen, cyano, nifro, Ci.6-alk(en/yn)yl, Ci-6-alk(en/yn)yloxy, Ci-6-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-Ci-6-a]k(en/yn)yl, halo-C]-6-alk(en/yn)yl, halo-Ci-e- alk(en/yn)yloxy, C3-s-cycloalk(en)yl, C3-8-cycloaU<: acyl c or ci-g-all such as phenyl substituted with one two subtituents typically selected from ci-s-aucyl ci-e-alkoxy e.g. methoxy cyano. in a further embodiment of formula i r is monocyclic heteroaryl thiophenyl.> In a fiirther embodiment of fonnula I, R' is hydrogen. In a further embodiment, R'^ is selected from Ci-e-aUcyl, such as methyl, ethyl, n-propyl, isopropyl or t-butyl. In a further embodiment, R** is selected from a halogen, such as CI, F, Br or I. In a fiirther embodiment of fonnula I, R"* is -NR'^'R'"' wherein R'-' and R'' independently are selected from hydrogen, Ci-6-a!k(eii/yn)yl, C3-a-cycloalk(en)yl, C3-B-cycloalk(en)yl-Ci-6 alk(en/yn)yl or aryl. In a further embodiment of formula I, R*" is -NR^^R'** wherein R'^ and R'' together with the nifrogen form a 3-7-membered heterocyclic ring selected from 1-morpholinyl, 1-piperidinyI, 1-pyrrolidinyl, l-azepinyl, l-piperazuiyl, l-homopiperazinyl, l-iraidazolyl, 1-pyrroIyl or 1-pyrazoIyl, optionally substituted with a Ci.6-allcyl In a further embodiment of fonnula I R' is phenyl optionally substituted with a halogen, cyano, nitro, Ci.6-alk(en/yn)yl, Ci-6-alk(en/yn)yioxy, Ci,6-allc(en/yn)ylsulfanyl, hydroxy, hydroxy-Ci-6-alk(en/yn)yI, halo-Ci-6-alk(en/yn)yl, haIo-C|.6-alk(en/yn)yloxy, C3-8-cycloalk(en)yl, C3-B-cycloallc(en)yl-Ci.c-alk(en/yn)yl, acyl Ci-6-alk(en/yn)yloxycarhonyl or C!-6-alk(en/yn)ylsulfonyl, such as phenyl substituted witli one or teo subtituents, typically one, selected from Ci^e-all^yl or Ci. In a further embodiment of formula I, R^ is phenyl. In a forther embodiment, R" is phenyl substituted with a halogen, C].(,-^\kyl, CK6-alkyloxy, Ci-Q-alkylsulfanyl, halo-C]_6-alkyl. The phenyl ring may contain I, 2, 3. 4 or 5 substituentS; typically 1 or 2 substituents independently selected from the above, such as CI, F, methyl, t-butyl, methox}', methylsulfanj'l or CF3. To illustrate this, without limiting the invention in any way, the following sub-structure of formula lis an embodiment of the invention; wherein R^ R^ R\ R*, R^ R^ R^ R^ R^', R'^ X and Y are as defined in foimula I above, including the described embodiments above and below, and R^', R'^ R'^, R^° and R^' are independently selected from H, halogen, Ci-s-alkyl, Ci-e-alkyloxy, C\.fr aUcylsulfanyl, halo-Ci-e-allcyl. In an embodiment R' is H. In an embodiment R'^ is selected from H; halogen, such as CI, or F; halo-Ci^-aJliyl, such as CF3; or Ci^-alkyl, such as methyl. In an embodiment R'^ is selected from H; halogen, such as CI, or F; halo-Ci-fi-alkyl, such as CF3; Ci-g-alkyl, such as methyl, or t-butyl; Ci-s-alkylstilfanyl, I such as -SCH3; or Ci-g-allcyloxy, such as methoxy. In an embodiment, R^° is selected from H; halogen, such as CI orF;halo-Ci.6-alkyl, such as CF3; orCi.fi-alkyl, such as methyl. In an embodunent R^' is H. Typically, R^' and R^' are both H, and one or two of R'^, R'*' and R^° is H, and the remaining substituent(s) is as defined above. In a fui-ther embodiment, R'^,R' andR-' are all H, and one of R'^ andR^' is halogen, such as F, and the other is hydrogen. In a fiuther embodiment of formula L R^ is naplithyl, such as 1-naphthyh or 2-naphthyl. In a further embodiment, R^ is naphthyl substituted with a halogen, Ci^s-alii^'i, Ci_6-alkyloxy, Ci-s-all-cylsulfanyj, halo-Ci-fi-alkyl. The naphthyl may contain 1, 2, 3, 4 or 5 substituents, typically 1 or 2 substituents independently selected from the above, such as CI, F, methyl, t-butyl, methoxy, methylsulfanyl or CF3. In a fiirther embodiment of formula I, R^ is monocyclic heteroaryl, optionally substituted with a halogen, cyano, nitro, C]-6-a!k(en/yn)yl, Ci_6-aIlc(en/yn)yloxy, Cj-e-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C!.G-alk(en'yn)yI, halo-Ci,6-alk(en/yn)yl, halo-Ci.6-aD£(en/yn)yloxy, C3.8-cycloalk(en)yl, C3.E-cycloaik(en)yl-Ci-6-alk(en/yn)yl, acyl, Ci-6-alk(en/yn)yioxycarbonyl, Ci.6-alk(en/yn)ylsulfonyl or -NR^^R^*" wherein R"^ and R' independently are selected from hydrogen, Ci.5-alk(en/yii)yl, Cs-g-cycloalk(en)yl, C3.B-cycloalk(en)yl-C].6 alk(en/yn)yl or aryl, orR^^ andR'^ together with the nitrogen form a 3-7-membered heterocyclic ring wliich optionally contains one further heteroatom selected from 0, S or N. Typically such monocyclic heteroaryl is selected from oxathiazoles, dioxazoles, dithiazoles, oxadiazoles, thiadiazoles, triazoles, isoxazoles, oxazoles, isothiazoles, thiazoles, imidazoles, pyrazoles, pyrroles, flu:an(s), thiophene(s), oxathiazines, dioxazines, dithiazines, oxadiazines, thiadiazines, triazines, oxazines, thiazines, pyrazines, pyridazines, pyrimidines, oxathiins, dioxins, dithims, pyiidines, pyrans or thins, In a further embodiment of formula I, R*^ is H. hi a further embodiment, R^ is C1.6-alkyl, such as methyl. In a further embodiment of formula I, R^ is Ci-g-alk(eii/yn)yloxy, such as Ci-6-alkyloxy, e.g. methoxy, provided that X is CR^^R'\ wherem R' ' and R^^ independently are selected from H, or Ci-e alkyl. In a fui-ther embodiment of formula I, R'^ is Ci.6-alk(en/yn)ylsulfanyl, such as Ci-s-alkylsulfanyl, e.g. methylsulfanyl, provided that X is CR"R^^ wherein R'^ and R^^ mdependently are selected from H or Ci-e alkyl. In a further embodiment of formula I, R' is H. In a further embodiment R^ is Ci.6-all-:yL such as methyl, ethji or isopropyl. In a further embodiment, R' is Cs-g-cycIoalk(en)5'I. such as Cs-^-cycioalicyl, e.g. cyclopropyl, cyciopenty] or cyclohexyl. In a fLiither embodiment of fonuula I, R^ is H. hi a further embodiment R^ is Ci-g-alkyl, such as methyl, ethyl or isopropyl. hi a farther embodiment, R^ is C-i.g-c>'cIoalk(eii)yI, such as Cj-E-cycIoalkyI, e.g. cyclopropyl, cyclopentyl or cyclohexyl. hi a huther embodiment of fonnula I, R^ is H. In a further embodiment, R"^ is Ci-^-ail<:yl such as methyl ethyl or isopropyl. in a further embodiment r is hydroxy-ci-e-alk hydroxy-cj-e-alkyl e.g. hydroxymetiiyl. flirther ci-6 alk c alkylsuifaiiyl-ci-u-aikyl methyisutfanylethyi.> In a further embodiment of fonnula I, R^ is H. In a fiirther embodiment, R^ is Ci.(3-allcyl, such as methyl, ethyl or isopropyl. In a fiirther embodiment, R^ is hydroxy-Ci-G-aUc(en/yn)yi, such as hydroxy-Ci-e-alkyl, e.g. hydroxymethyl. In a further embodiment, R^ is CI-G alk(en/yn)yisulfanyl-Ci-6-alk(en/yn)yi, such as Ci.6 alkylsuIfanyI-Ci-6-alkyI, e.g. methylsulfanylethyl. Typically, one of R" andR^' is a hydrogen, however, they may both be independently selected from Ci-e-alkyl, such as methyl, ethyl or isopropyl; hydroxy-Ci-6-ailc(en/yn)yl, such as hydroxy-Ci.6-aikyI; or Cue aIk(en/yn)ylsulfanyI-Ci.6-allc(en/yn)yl, such as Ci-e alkylsulfanyl-C|.fi-alkyl. In a further embodiment of formula I, R'" is H. In a furtlier embodiment of formula I, R^ and R^ together with the nifrogen form a saturated 3-7 membered heterocyclic ring, and R' is selected from H, Ci-e-aUc(eii/yii)yl or C3-s~cycloallc(en)yl, and R^ and R^' are independently selected from H, Ci.G-all wherein R' , R^ R^ R^ R^ R"^, R^, R^', R^°, X and Y are as defined in formula I above, including the described embodimems. In a further embodiment of formula I R^ and R^ together with the nitrogen form a saturated 3-7 raenibered heterocyclic ling, and R"^ is selected from H, Cr_6-alk(en/yn}yl, C]-fi-alk(eii/>n)-yloxy, C,.ii-alk(en/yn)ylsulfariyl or C3-s-cycloalk(en)y], provided that when R is selected &om Ci-s-alk{en/yn)yloxy or Cuts-alk(eii/ya)ylsulfanyl then X is CR^'R'^ wherein R" and R'^ independently are selected fi-om H or C1.1; alkyl, and R' is selected &om H, Ci-6-alk(en/yn)yl oj- C3-S-cycloalk(en)yl, and R^ is selected from H, Ci-6-alk(en/yii)yl, hydroxy-C|.6-ailc(en/yn)yl, Ci-s aIk(en/'yn)yIsulfanyl-Ci.6-a!k(en/yn)yI or C3.g"CycIoaIk(en)yl. To illustrate this, without limiting the invention in any way, the foUowuig sub-stiticture of foiTnula I is an embodiment of the invention; (le) wherein R' , R^ R\ R*^, R^ R^ R\ R^', R'°, X and Y are as defined in formula I above, including the described embodiments, and the asterix means that the carbon atom whereto R°' is attached is a chiral center. In one embodiment of formula le, the * designates a racemic mixture of the R- and S-isomer. In a further embodiment of formula le, the * designates the R-isomer. in a further embodiment of formula le, the * designates the S-isomer. In further embodunents of formula I, the compoimd is any one of {S)-l-{2-[2-(4-Fluoro-pheEylsulfa3iyl)-phenoxy]-ethyl}-pyrrolidme-2-carboxyiicacid, (S)-l-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxyUc acid, (S)-1 - {2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyI] -pyrTolidine-2- carboxyiic acid, (S)- l-{2-[2-(3-Fluoro-phenyisulfanyl)-phenoxy]-ethyI)-pyrrolidine-2~carboxylic acid, (S)-{2-[2-(4-ChlorD-phenylsulfai-iyl)-phenoxy]-ethyl}-pyiTolidine-2-carboxylic acid, (S)'l-{2-[2-f3-Chloro-pbenylsulfanyl)-phenoxy]-ethyl}-p}'rroIidine-2-carboxylic acid, (S)-l-{2-[2-(3,4-Dichloro-plienylsiilfanyl)-phenoxy]-ethyli-pyn-olidine-2-carboxyUc acid, (S)-]-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid, (S)-l-{2-[2-(3-Chloro-pIienoxy)-pheHOxy]-ethyl}-pyrro]idine-2-carboxylic acid, (S)-1"{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid, (S)-l-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-etiiyl}-pyrrolidine-2-carboxylic acid, (S)-1 - {2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl} -pyrrolidine-2-carboxylic acid, l-{2(R/S)-[2-(4-Qiioro-phenoxy)-phenoxy]-propyl}-pyrroliduie-2(S)-carboxylic acid, l-{2(R/S)-[2-(3,4-Difluoi'o-phenoxy)-plienoxy]-pn3pyI}-pyiTolidine-2(S)-carboxyiic acid, {S)-l-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyI}-pyrrolidine-2-carboxylic acid, l-{2(R/S)-[2-(3~Fluoro-phenoxy)-phenoxy]-propyl}-pyrroUdine-2(S)-carboxylic acid, l-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrroUdine-2(S)- carboxylic acid, l-{2CRyS)-[2-(3-Chloro-phenylsulfany!)-phenoxy]-propyl}-pyrrolidine-2(S> carboxylic acid, ({2-[2-(4-tert-Butyl-pl3eny]sulfany])-phenoxy]-ethyl}-N-ethy]-aininD)-aceticacid, 2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl}-propionicacid, ({2~[2-(3-ChlQro-phenylsulfanyl)-phenoxy]-etliyl}-N~metiiyl-ainino)-aceticacid, ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-inethyl-amino)-acetic acid, {2-[2-(4-tert-Butyl-phenylsulfanyI)-phenoxymethyl]-piperidiii-l-yl}-aceticacid, ({2-[2-(3-Fluoro-pheiiylsulfaiiyl)-plienoxy3-ethyl} -N-metliyl-amino)-acetic acid, {4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-l-yl)-aceticacid, (N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amirio)-ace1ic acid, ({2-[2-(3,4-Dichloro-phenyIsuJfanyl)-phenoxy]-ethyl}-N-etIiyI-amino}-acetic acid. (>^-Ethyl-{2"[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-ammo)-acetic acid, 2-{3-[2-(3.4-Dichloro-phenylsulfaiiyl)-phenoxy]-p^-rrolid!n-l-yI}-propionic acid, (S)-(3-r2-(4-tert-Bu:yl-pheny!sulfanyI)-phenoxy]-pyn-olidin-l-yl}-acetic acid, ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-etIiyl}-N-etliyl-amino)-acetic acid, (N-2-propyl-{2-[2-(4-methy]sulfanyl-phenylsulfaHy])-phenoxy]-ethyl}-ainiHo)--acetic acid, {3-f2-(4-tei1-ButyI-phenyisuIfany!}-phenoxyl-p>tTolidin-l-yi}-acetic acid, ({242-(3-Chloro-phenylsiUfanyl)-phenoxy]-ethyl}-N-etliyl-ainino)-acetic acid, ({2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyI-}N-methyl-aniino)-acetic acid, {4-[2-(3,4-Dichloro-phenyIsulfanyl)-phenoxy]-piperidiii-]-yl)-acetic acid, 2-{3-[2-(4-Trifluoroin6thyl-plienylsulfanyI)-phenoxy]-pyn:olidin-l-yl}-propiomc acid, ({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid ({2-[2-(4-tert-ButyI-phenylsulfanyl)-phenoxy]-ethyl} -N-i'nethyI-amino)-acetic acid, {2-[2-(4-Methylsulfanyl-pheiiylsulfaiiyl)-phenoxymethyl]-piperidiii-l-yl}-acetic acid, ({2-[2-(3,4-Dichloro--phenylsulfaiiyl)-phenoxy]--ethyl}-N-methyl-ai)iLno)-acetic acid, (N-Methyl-{2-[2-(4-trifIuoromethyl-pheny]suIfanyl)-pbenoxy]-ethy]}~amino)-acetic acid, 2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyiTolidin-l-yl}-propionic acid, 2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyI)-phenoxy]-pyiTolidin-l-yl}-propioiiic acid, 2-[3(R)-(2-(4-metiiylphenyl)-sulfanyl-phenoxy)-pyrrolidin-l-yl]-propionic acid, {3(R)-[2-(4-tert-Butyl-pheDylsulfanyl)-pheDDxy]-pyrrolidin-3-yl}-aceticacid, 2-{3(R)-[2-(4-Trifluorometiiy]-phenylsulfanyl)-phenoxy]"pyiTolidin-l~yl}-propiomc acid, 2-{3(R)-[2-(4-Chloro-plienylsulfanyl)-plienoxy]-pyrrolidin-l-yl}-propiomcacid, ({l-t2-(3-Cliloro-phenylsulfanyl)-phenoxyinethyl]-propyi}-N-ethyl-amno)-acetic acidj ({l"[2-(3,4-Dichloro-phenyisulfanyl)-pheiioxy)-butan-2-yl}-N-ethyl-amino)-acetic acid, ({l-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]~butan-3-met]iyl-2-yl}-N-ethyl- amino)-acetic acid. ({i-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid, ({l-[L-(3-Chloro-plienylsulfaiiyI)-plienoxy]-propan-2-y]j"N-ethyl-aniino)-acetic acid, ({l-[2-(3-Cliloro-4-fluoro-phenylsulfanyi)-phenoxy]-butaii-4-mediyl-2-yl)]-N-ethyl-amino)-acetic acid, ({l-[2-(3-Chloro-4-iluoTO-phenylsulfaiiyl)-phenoxy]propa.Ti-2-yI)-N-ethyl-amino)- acetic acid, (SV(l-[2-(3-Chloro-phenyIsulfaiiyl)-phenoxy]-propan-2-yl }-N-methyl-aniino)-acetic acid, (S)-({142-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yI)-N-ethyI-amiiio)-acetic acid, ({1 -[2-(3,4-Dichloro-phenylsulfaiiyl)-phenoxy]-propan-2-yl} -N-ethyl-amino)-acetic acid, ((l-[2-(4-CliIoro-phenylsuJfaiiyl)-phenoxy]-propaii-2-yl}-N-ethyi-amino)-acetic acid, ({l-[2-(3-Cliloro-phenylsulfaiiyl)-phenoxymethyl]-propyl}-N-methyl-amino)-acetic acid, ({1 -[2-(4-ClTloro-phenylsulfanyl)-phenoxyinethyl]-propyl} -N-ethyl-amino)-acetic acid, (N-Etliyl- {1 -[2-(3-fluoro-phenylsulfany])-phenosymethyl]-propyl}~amino)-acetic acid, (Tl)-({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-l--methyl-ethyl}-N-etliyl-amiiio)-- acetic acid, (S)-(2{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-aceticacid, (R)-(2{2-[2-(3-Ch]oro-phenyIsuIfanyl)-phenoxy]-}-propy!-N-inethyl-ainino)-acetic i acid, ({2-[2-(3-Fluoro-plienylsulfaiiyl)-phenoxy]-propyI}-N-methyi-aniino)-aceticacid, ({242 ({l-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-inethyl-butaii-2-yl}-N-methyl-amino)- acetic acid, ) ({3-methyl-l-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl- amino)-acetic acid, ({l-[2-(3-Chloro-4-fluoro-pheny!sulfanyl)-phenoxy]-butaii-2-yl}-N-methyI-ainino)- acetic acid. (S)-(l{2-[2-(3-Cliioro-4-fluoro-phenylsulfanyI)-phenoxy]-propan-2-yl}N-methyl-aminoVacetic acid, (S}-(2-{2-[2-('3-Fluoro-phenylsiilfany])-phenoxy]-propyi}-N-methyl-aniino)-acetic acid. ({l-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-niethyl-butan-2-yl}-N-ethyl-amino)-acelic acid, (S)-({l-[2-(3,4-DichIoro-phenylsulfanyl)-phenoxy]-propaii-2-yl}-N-methyl-amino)- acetic acid, ({l-[2-(3-Cliloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butaii-2-y])-N-methyl- atnino)-acetic acid, ({l-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-mefeyI-propaii-2-yl}-N-ethyl- amino)-acetic acid, ({2-[2-{3-Chloro-4-fluoro~phenylsulfanyl)-phenoxy]-propan-l-yl}-N-ethyl-amino)- acetic acid, ({2-[2-{4-metlioxy-phenylsulfanyl)-phenoxy]-propan-1 -yl} - N-Cyclohexyl -amino)- acetic acid, { [2-(2-(4-methylsulfanyI-phenoxy)-propan-1 -yl-]-N-cyclohexyl-amino} -acetic acid, ({2-[2-(3-Cliloro-phenylsulfan.yl)-phenoxy]-propan-l-yl}-N-cyclohexyl-ai-nino)-acetic acid, (S)-l-{3-[2-(3-Fluoro-phenylsiilfanyl)-phenyl]-propyl}-pyirolidine-2-carboxylicacid, (S)-2-{{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-aniino)- propionic acid, ({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-metliyl-amino)-acetic acid, (S)-l-{2-[4-CIiloro-2-(3-fluoro-phenylsulfanyl)-pheiioxy]-ethyl}-pyrrolidine-2- carboxylic acid, {S)-l-{2-[3-Chloro-2-(3-fluoro-phenylsulfuiiyI)-phenoxy]-ethyI}pyrroIidine-2- carboxylic acid, (S)-l-{2-[5-Cliloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2- carboxylic acid, (S)-l--{2-[4-Cyano-2-(3-fiuoro-phenylsulfanyI)-phenoxy]-ettiyI}-pyrrolidine-2- carboxylic acid {S)4-[2-(5-Chloro-2-phenylsulfanyl-phenoxy)-etliyl]pyTT0lidine-2-carboxyIicacid, (S)-l-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-sthyl}-pyTrolidine-2-carboxylic acid, (S)-{2-[4'-Methoxy-3-('3-fluoro-phenylsulfanyl)-biphenyI-4-yloxy]-etliyI}-p>iTolidine-2-.carboxylic acid, (S)-{2-[4'"Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyI-4-yloxy]-etliyl}-p3'rrolidine-2-cai'boxylic acid, (S)-l-{2-[4'-Cyano-4-{3-fIuoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethy)}-pyrrohdine-2-carboxylic acid, (S)-l-{2-[2-(3-Fluoro-phenylsulfany!)-5~tliiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-cai'boxylic acid, (S)-l-(2-[2-(3-Fiuoro-phenylsulfanyl)-4-pyrimidm-5-yl-phenoxy]-ethyl}-p;TTolidine-2-carboxylic acid, (S)-l-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid, (S)-l-(2-[2-f3-FIuoro-phenyIsulfanyl)-4-morphofiii-4-yI-phenoxy]-ethyi}-pyrroIidme-2-carboxylic acid, {S)-l-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-l-yI-phenoxy]-ethyl}-pyrrolidme-2-carboxyIic acid, or a phamiaceutically acceptable salt thereof. Each of these compounds is considered a specific embodiment and may be subject to individual claims. The present invention also comprises salts of the present compounds, typically, pharmaceutically acceptable salts. Such salts include pharmaceutical acceptable acid addition salts, phamiaceutically acceptable metal salts, ammomum and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfiiric, sulfamic, nitric acids and the lilce, Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, flmiaric, glycolic, itaconic, lactic, methanesulfonic, maleic, mahc, malonic, mandehc, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic. pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-Toluenesulfonic acids, theophylline acetic acids, as well as the S-halotheophylHnes, for example 8-bromotheopbylline and the like. Further examples of pharmaceutical acceptable inorganic or organic acid addition salts include the phamiaceutically acceptable salts listed in J. Phann, Sci. 1977,66,2, which is incoiporated herein by reference. Examples of metal salts include hthium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammoni^ml salts include ammoriium, methyl-, dimethyl-, trimethyl-, ethyl-, hydroxyethyl-, diethyl-, n-butyl-, sec-butyl-, tert-butyl-, tetramethylammonium salts and the like. Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharraaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention. The compounds of tlie present invention may have one or more asymmetric centres and it is intended diat any optical isomers (i.e. enantiomers or diastereomers), as separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures are included within the scope of the invention. Racemic forms can be resolved into the optical antipodes by Icnown methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can also be resolved mto their optical antipodes, e.g. by fractional crystallization of d- or 1- {tartrates, mandelates or camphorsulphonate) salts. The compounds of the present invention may also be resolved by the formation of diastereomeric derivati"\'es. Additional methods for the resolution of optical isomers, loio-w'n to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in "Enantiomers, Racemates, and Resolutions", .Tohn Wiley and Sons, Nev/ York(19Sl). Optically' active compounds can also be prepared from optically active starting materials. Furthermore, when a double bond or a fully or partially saturated ring system is present in tlie molecule geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially pijrified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention. Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms that tlie compounds are able to form are included within the scope of the present invention. The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming pharmacologically active substances. In general, such prodrugs will be fimctional derivatives of the compounds of the general formula (I), which are readily convertible in vivo into the required compound of the formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, m"Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. The invention also encompasses active metabolites of the present compounds. As mentioned above, the compounds of formula I are potent inhibiters of the glycine transporter, and accordingly may be applicable for the treatment, including prevention, of schizophrenia, including both the positive and tlie negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cogiiitive processes are diminished, i.e. Alzheimer's disease, inulti-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the braui is damaged by umer or outer influence, such as trauma to the head or stroke, and com'ulsi^'e disorders such as epilepsy, spasticit;' ormyoclonus. Accordingly, in a farther aspect the uivention relates to a compound of fonnula I for use as a medicament. The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a phamiaceutically acceptable carrier or diluent. The composition may comprise any one of the embodiments of formula I described above. In an embodiment of the pharmaceutical corr^osition, the compound of formula I is present m an amount of from about 0.001 to about lOOmg/kgbody weight per day. The present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of a disease or disorder, wherein an inhibitor of the glycine transport is beneficial. The medicament may comprise any one of the embodunents of formula I described above. In particular, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of schizophrenia. Such schizophrenia includes both the positive and the negative symptoms of scliizophrenia and other psychoses. hi a fin-ther embodiment, the present mvention relates to use of a compound of formula I for the preparation of a medicament for the treatanent of Alzheimer's disease. In a farther embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatinent of multi-infarct dementia, hi a further embodiment, the present invention relates to use of a compound of foiTnula I for the preparation of a medicament for the treatment of AIDS. In a further embodiment, the present in^'ention relates to use of a compound of formula I for the preparation of a medicament for the treatment of dementia. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of Huntington's disease, hi a further embodiment, the present invention relates to use of a compomid of formula I for the preparation of a medicament for the treatment of Parkinson's disease. In a fiirther embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of amyoti-ophic lateral sclerosis. In a fiirther embodiment, the present invention relates to use of a compound of formula I for tlie preparation of a medicament for the treatment of diseases wherem the brain is damaged by inner or outer influence. In a further embodiment, the present invention relates to use of a compound of foimula I for the preparation of a medicament for the treatment of trauma to tlie head. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of stroke. In a iurther embodiment, the present invention relates to use of a compomid of formula I for the preparation of a medicament for the treatment of convulsive disorders. In a iurther embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of epilepsy. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of spasticity. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of myoclonus. In a further embodiment, the present invention relates to the use of a compound of formula I as above or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of post-traumatic stress disorder. The medicament may comprise any one of the embodiments of foimula I described above. A further aspect of the invention relates to a method for the treattnent of a disease or disorder selected from the group consisting of the positive and the negative symptoms of schizoplirema, including both the positive and the negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotropliic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to tlie head or stroke, and convoilsive disorders such as epilepsy, spasticity or myoclonus, in a livmg animal body, including a human, comprismg administering to a subject inneed thereof a therapeutically effective amount of a compound of foimula I. A further aspect of the invention relates to a method for the treatment of post-ti'aumatic stress disorder in a Hving animal body, mcluding a human, comprising administering a therapeutically effective amount of a compound of formula I as above or a pharmaceutically acceptable acid addition salt thereof In a further aspect, the present invention relates to a method of preparing a compound of formula I, comprising coupling an alcohol of formula II The reaction is typically performed in a suitable solvent such as tetrahydroftiran or diethyl ether containing a coupling agent such as triphenylphosphine aiid dieth3iazodicarboxylate or l,r-(A2od!carbonyl)dipiperidine at room temperature. Alternatively, tlie present invention relates to a method of preparing a compound of fomiulal, comprising alleviation of an amine offonnulalV wherein R' , R^ R^ R^ R^ R^ R^ R^ R^ R^', R^°, X and Y ai-e as defmed in formula I above, and L is a suitable leaving group such as halogen, mesylate or tosylate. The reaction is typically performed in a suitable solvent such as ethanol, N,N-dimethylformamide or acetonitrile containing an inorganic base such as potassium or cesium carbonate or an organic base such N-ethyl diisopropylamine at an elevated temperature of 40-80 °C. Alternatively compounds of formula I may be prepared by coupling intennediates of of formula VI where Z is an iodide, R'-R'" are as described above and Y is sulfur. The cross coupling reaction is typically perfoimed as described by Schopfer (Tetrahedron, 2001, 57, 3069-3073) where an iodide of formula W is coupled to a thiol of formula R^-S-H using palladium catalysis in toluene at elevated temperatures. Compounds of fonnuia I wherein R'° is hydrogen may he prepared by hydrolysis of the corresponding esters COOR wherein R^" is an insoluble polymer or e.g. Ci-e-allcyl, aryl or aryl-Ci,6-alkyl. This may be performed under basic conditions, for example, using aqueous sodium hydroxide in an alcoholic solvent or under acidic conditions in the hydrolysis of a tertiary-butyl ester or cleavage from an insoluble polymer. TMs, method is also an aspect of the present invention. Pharmaceutical compositions The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack PublisMngCo„Easton,PA iQQ'^ The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracistema!, intraperitoneal, vaginal and parenteral (including subcutaneous, intramusculai-, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the prefeiTed roule will depend on the general condihon and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen. Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, iozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or tliey can be form-ulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art. Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs. Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injetable formulations are also contemplated as being within the scope of the present invention. Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants, etc. A typical oral dosage is in the range offrom about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more prefen-ed from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those sldlled in the art. The formulations may conveniently be presented in unit dosage form by metliods Icnown to those skilled in the art. A typical unit dosage forra for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.01 to about 1000 mg, preferably from about 0.05 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg. For parenteral routes such as intravenous, intratliecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration. The compounds of this mvention are generally utilized as the free substance or as a phaimaceutically acceptable salt thereof. One example is a base addition salt of a compound having the utility of a free acid. When a compound of the formula (I) contains a free acid such salts are prepared in a conventional maimer by treating a solution or suspension of a free acid of the formula (I) with a chemical equivalent of a pharmaceutically acceptable base. Representative examples are mentioned above. For parenteral administration, solutions of the novel compounds of the formula (I) in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oU may be employed. Such aqueous solutions should be suitably buffered if necessary and the Uquld diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, inframuscular, subcutaneous and infraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. Suitable pharmaceutical carriers include inert soHd diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower aUcyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water. Smiilarly, the carrier or diluent may include any sustained release material laiown in the an, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax- The pharmaceutical compositions formed by combining the novel compounds of the formula (I) and the pharmaceutical acceptable carriers are then readily administered in a variety of dosage fomrs suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods Icnown in the ait of pharmacy. Fonnulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined, amount of the active ingredient, and which may include a suitable excipient. Furthermore, tlie orally available fomiulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion. If a solid carrier is used for oral administration, the preparation may be tablette, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable hquid such as an aqueous or non-aqueous liquid suspension or solution. Method of preparing the compounds of formula I The compounds of the invention are prepared by the followmg general methods. Coupling of alcohol of formula n with a phenol of formula IH The cross coupling reaction is typically performed as described by Schopfer (Tetrahedron, 2001, 57. 3069-3073) where an iodide of fonnula VI is coupled to a thiol of formula Vn, R"^-S-H using palladium catalysis in toluene at elevated temperatures. Compounds of formula I wherein R"* is hydrogen may be prepared by hydrolysis of the corresponding esters COOR^'^ wherein R^'* is an insoluble polymer or Cue-alkyl, aryl or aryl-Cu5-allcyl. This may be performed under basic conditions, for example, using aqueous sodium hydroxide in an alcoholic solvent or under acidic conditions in the hydrolysis of a tertiaiy-butyl ester or cleavage from an insoluble polymer. Compounds of formula H may be prepared as depicted in scheme \. magnesium (Gilman, Reel. Trav, Chim. Pays-Bas 1935, 58S) or lithium (Hader et al, J.Oj-gaiiomet.Chem. 1989, 364, 1-16) and reacted with bis aryl bissulfides. Alternatively 2-halo-anisoles in the case of the halogen being iodide may be coupled using palladium'phosphine catalysis with a tiiiophenol as described in the general method of Schopfer (Jetrahdron 2001,57 , 3069-3073 to give intermediates, after demethylation of the anisole, of foimula HI. Intermediates of fomiula IN are typically conunercially a^'ailable or their syntheses are well described in the literature. Compounds of formula V where X is 0 may be prepared by reacting intermediates of formula III with ethylene carbonate to give the O-hydroxy ethyl derivative which can then be converted to compounds of formula V. Where L is CI this could be using carbon tetrachloride and triphenylphosphine in dichloromethane. In the case of tosylate and mesylate this could by the use of tosyl chloride or metliane sulfonyl chloiide respectively in a solvent such as dichloromefhane or tettahydrofuran. These methods are standard to those skilled in the art. Compounds of formula V where X is carbon may be prepared by the alkylation of suitably substituted 2-iodo-benzylhalides with diethyl malonate in the general procedure described by L.F. Fieser, E. Berliner, J. Am. Chem. Soc. 1952, 74, 536 to give 2-iodo-pheiiylpropioTiic acids. In tlie cast of X is sulfur, coupling with an appropiate thiophenol using copper catalysis according to the method of Bartl et al, Collection Czechoslovak Chem. Commun, 1981, 46, 141 affords the 2-(arylsulfanyl)phenyl propionic acid which can be reduced using standard methods such as borane-tetrahydrofuran complex or lithium aluminium hydride to 2-(arylsulfanyl)phenyl propanol. Activation of the alcohol to nucleophilic displacement can be performed as described above. Compounds of formula VI may be prepared by the reaction of intermediates of fomiula n with intermediates of formula XII. The substituents R'-R'° are as defined above, X is oxygen, sulphur or CR' 'R'^, wherein R' ' and R'^ are as defined above, and Z is an iodide. The reaction is typically performed in a suitable solvent such as tetrahydro&ran or diethyl ether containing a coupling agent such as triphenyl pliosphiiie and diethylazodicarboxylate or l,r-(AzodicarbonyI)dipiperidine at room tsmperatm-e. Intermediates of formula XII where Z is an iodide are commercially available or can be easily obtained by demsthylation of the corresponding 2-iodo-aiiisole using for example boron tribromide in toluene or similar methods well known to those skilled in the art. Alternatively ti-eatment of tlie corresponding anisole with tert-butyl lithium and quenching with iodine as descrived by Iwao {J. Org. Chem. 1990, 55, 3622-3627) and subsequent demethylation will also provide intermediates of formula XII. A third approach is the conversion of the appropiate 2-inefhoxy aniline derivative to the iodide in a Sandmeyer reaction as described by Still (J. Org. Chem, 1987, 52, 748-753), followed by demethylation to give intermediates of formula XII. These methods are all well described in the literature. Examples of formula I may also be prepared by modifications of formula I where R'-R* can be a bromide or iodide and R^" is as defined above but not hydrogen. In this approach the intermediates as described may be reacted with for example with a aryl or heteroary] boronic acid or ester using Suzuki conditions to afford the appropriately substituted aryl or heteroaryl derivative.. Alternatively reaction with an amine using palladium catalysis allows access to examples where the bromide or iodide is replaced with the amine in examples of formula I. Examples Genera) Methods .Analytical LC-MS data were obtained on a PE Sciex API I50EX instrument equipped v/ith lonSpray source and Shimadzu LC-S.VSLC-lOA LC system. Column: 30 X 4,6 inni Waters Syniinnietr>'- C18 column with 3.5 inn particle size; Solventsystem: A = W'at er/trifluoro acetic acid (100:0,05) and B = water/acetonitrile/trifluoro acetic acid (5:95:0.03); Method: Linear gradient elution with 90% A to 100% B in 4 min and with a flow rate of 2 mL/min. Purity was determined by integration of the UV (254 mn) and ELSD trace. The retention times (RT) are expressed in minutes. Preparative LC-MS-purification was performed on the same instnmient. Column: 50 X 20 mm YMC ODS-A with 5 jini particle size; Metliod: Lmear gradient elution with 80% A to 100% B in 7 min and with a flow rate of 22.7 mL/min. Fraction collection was performed by split-flow MS detection. 'H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Deuterated nethyienchloride (99.8%D), chloroform (99.8%D) or dimethyl sulfoxide (99.8%D) were used as solvents. TMS was used as internal reference standard. Chemical shift /alues are expressed in ppm-values. The following abbreviations are used for ntiltiplicity of NMR signals: s = singlet, d = doublet, t = triplet, q = quartet, qui = pintet, h = heptet, dd = double doublet, dt = double triplet, dq = double quartet, tt = riplet of triplets, m = multiplet and b = broad singlet. 'or ion-exchange chromatography, the following material was used: SCX-columns (1 ;) from Varian Mega Bond Elut®, Chrompack cat. No. 220776. Prior to use, the ICX-columns were pre-conditioned with 10% solution of acetic acid in methanol (3 tiL). For de-complexation by irradiation, a ultaviolet light source (300 W) from 'liilipps was used. olymerbound PPhs (0.93 mmol/g, 100-200 mesh) was purchased from Senn Chemicals. Preparation of latermediates of Formula XI l-CyclohexylaminO'propan-2-oI Cyclohexanone (0.98 g, lOnunol) and 1-amino-propan-2-ol (0,75g, 10 rnitiol) were mixed and MeOH (20 nil..), acetic acid (12 mg, O.S nmiol), cyanoborohydride resin (7 g, 14 iiamol, 2 nrmol/g, prepared as described by A.R. Sande et al, Teti-ahedron Letters 1984, 3501) were added. The reaction mixture was heated under reflux for 16 h. The resin was filtered off and the filtrate was e-\'aporated in vacuo. The crude product was used without further purification. 2~(tert'Butyl-dimethyl-silanyloxy)-propylamine /e7Y-Butyl-chloro-diniethyI-silane (2.6 g 17 mmol) was dissolved in DCM (20 mL). 1-Anuno-propan-2-ol (1.2 g, 16 mmol), triethylamine (2.2 mL, 16 mmol) and a catalytic amount of DMAP were added. The reaction mixture was stirred for 16 h. Water (10 mL) was added and the phases were separated. The aqueous phase was extracted with EtOAc (2 X 100 mL). The combined organic phases were dried over magnesium sulfate, filtered and the filtrate was evaporated in vacuo. The product was isolated as an oil. Yield: 2.4 g, S0%. The following intermediates were prepared in an analogous fashion: 2-(tert-Butyl'dimethyl-silanyloxy)-l-methyl-ethylamine I - (teri-Butyl-dimethyl-silauyloxymethyl) -propylamine }-(tert-Buiyl-dimethyl-silanyloxymet'hyl)-2-methyl-propylamine l-(S)-2-(tert-Butyl-dimethyl~silanyloxy)')-methyl~ethylamine l-(R)~2-(tert-Butyl-dimethyl-silanyloxy)-methyl'ethylamine Preparation of Intermediates of Formula II (2~Hydroxymethyl~pipe}'idin-l-yl)-acetic acid tert-butyl ester Bromo-acetic acid tert-hutyl ester (0.39 g, 2 mmol) was dissolved in DMF (1 mL). A solution of piperidin-2-yl-methanol (0.25 g, 2.2 mmol) in DMF (1 mL) and diisopropyiethylamine (0.38 mL, 2.2 mmol) was added. The reaction mixture was stiiTed at SO'^C for 16 h. The solvent was removed in vacuo. EtOAc (20 mL) and water (7 niL) was added. The two phases were separated. The aqueous phase was extracted twice with EtO Ac (20 mL). The combined EtOAc phases were dried over magnesium sulfate, filtered and the filtrate was evaporated in vacuo. The product was isolated as an oil. Yield: 0.37 g, 80%. The following intermediates were prepared in an analogous fashion: [(2~Hydroxy'ethyl)-methyl-amino]-acetic acid tert-biityl ester [EthyI-(2-hydroxy-ethyl)~amino]-acelic acid tert-buty} esrer [(2-Hydroxy-ethyl)-isopropyl-amino]~acetic acid tert-btityl ester (4-Hydroxy'piperidin-l-yl)-acetic acid tert-buTyl ester (3'Hydroxy-pyrrolidin-l-yl)-acetic acid tert-butyl ester (R)'(3-Hydroxy-pyrrolidin-l-yl)'-acetic acid tert-buiyl ester 2-(3-Hydroxy-pyrrolidin-l-yI)-propionic acid tert-butyl ester (S)'(3-Hydroxy-pyrrolidin-}-'yl)-acetic acid tert-butyl ester (S)-2-(3-Hydroxy-pyrrolidin-l-yl)-propionic acid tert-butyl ester [Cyclohexyl-(2-hydroxy-propyl)-amino]-acetic acid tert-butyl ester [2-(tert-Butyl-dimethyl-silanyloxy)-propylamino]-acetic acid tert-butyl ester 2-(tert-Butyl-dhnethyl-silanyloxy)-propylamine (6.0 g, 31.6 mmol) was dissolved in DMF(60mL). Diisopropylethylamine (5.5 mL, 31.6 mmol) and bromo-acetic acid iert-buty] ester (3.6 g, 18.6 mmol) was added. The reaction mixture was stirred at 50 °C for 16 h. The mixture was evaporated onto sihca gel and and purified by column chromatography using a gradient, starting eluting with ethyl acetate/heptane 20-.80 up to ethyl acetate/heptane 80:20. The product was isolated as an oil. Yield: 4.0 g, 71%. The following mtermediates were prepared in an analogous fashion: [2'(tert-Butyl'dimethyl-silanyloxy)'l-viethyl-ethylaminoJ'acetic acid tert-butyl ester [l'(tert-Butyl-dimethyl-silanyloxymethyl)-propylamino]'acetic acid tert-butyl ester [}'(tert-Butyl-dimethyl-silanyloxymethyl)-2-methyl-propylamino]-acetic acid tert-butyl ester (S)'[2-(tert'Butyl-dimethyl'Silanyloxy)'l-methyl-ethylamino]-aceticacid (R)~l2-(tert-But}>l-dimethyl-silanylox)')-l'methyl-ethylamino]-acetic acid lert-bufy^ ester [E:.hyi-{2-hydrox}>-pTopyl)-ainino]-acetic acid terl-but)!l ester [2-(tert-Butyl-diraethyl-silanyloxy)-propylamino]-acetic acid tert-butyl ester (1.2 g, 4 imnol) and diisopropylethylamine (9.7 ml-, 56 mniol) was dissolved in DMF (20 mL), lodo-ethaiie (2.6 mL, 32 inmol) was added. The reaction was stirred at 50 "C for 16 h. Tlie solvent was removed in vacuo. The crude product was dissolved in EtOAc (100 mL) and the solution was washed w^ith water (20 mL). The organic phase was dried over magnesium sulfate, fihered and the filtrate was evaporated in vacuo. The residue was dissolved in acetonitrile (30 mL) and EtaN 3HF (1.3 mL, S mmol) was added. The reaction was stirred for 16 h. The solvent was removed in vacuo. The crude product was dissolved in EtOAc (100 mL) and washed with saturated sodium bicarbonate solution (25 mL) and saturated sodium chloride solution (25 mL). The organic phase was dried over magnesium sulfate and the solution was slowly filtered through 5 g of sihca gel. The filtrate was evaporated in vacuo. Yield: 0.17 g, 20%, The following intermediates were prepared in an analogous fashion: fEthyl-(2-hydroxy-J-methyl-ethyl)-amino]'acetic acid tert-butyl ester [Ethyl-(l-hydroyymethyl-propyl)-amino]-aceticacidtert-butyl ester [Ethyl'(}-hydroxymethyl-2-methyl-propyl)'amino]-acetic acid tert-but^d ester (S)-[Etkyl-(2-hydroxy-1-methyl-ethylj-amino]-acetic acid tert-butyl ester (R)'[Ethyl-(2-hydroxy-l-m.ethyl-ethyl)-amino]'acetic acid tert-butyl ester Preparation of Intermediates of Formula II [(l-Hydroxymethyl-2-methyl-propyl)-methyl-amino]~acetic acid tert-butyl ester {[l-(len-Butyl-dimethyl-silanyloxymethyl)-2-methyl-propyl]-ammo}-acetic acid tert-butyl ester (1.9 g, 6.1 mmol) and diisopropylethylamine (4.2 mL, 24 mmol) were dissolved in DMF (15 mL). A solution of Mel (0.45 mL, 7.3 mraol) in DMF (100 mL) was slowly added over 15 min. The reaction was stirred for VA h. The solvent was removed in vacuo. The residue product was dissolved in EtOAc (100 mL) and the solution was washed with water (20 roL). The oreanic phase was dried over magnesium sulfate, filtered and the filtrate was evaporated in vacuo. The residue was dissolved in acetonitrile (45 mL) and EtjN 3HF (2 niL, 12.3 mmol) was added. The reaction was stirred for 16 h. The solvent was removed in vacuo. The crude product was dissoh'ed in EtOAc (100 mL) and washed ^'i'itli saturated sodium bicarbonate solution (25 mL) and saturated sodium chloride solution (25 niL). The organic phase \'i'"as dried over magnesium sulfate and the solution was slowly filtered through 5 g of sihca gel. The filtrate was evaporated in vacuo. Yield: 1.1 g, 78%. The following intennediates were prepared in an analogous fasMon: [(2-Hydroxy-l-methyl-ethyl)-mcthyl-amino]-acetic acid lert-hutyl ester [(l~Hydroxymethyl-propyl)-methyl-amino]-acetic acid tert-butyl ester (S)-[(2~Hydroxy~l-methyl'ethyl)-methyl-amino]-acetic acid tert-butyl ester (R)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester [(2-Hydroxy-propyl)-methyl-amino]-acetic acid tert-butyl ester Preparation of Intermediates of Formula II using Intermediates of Formula VTTI and Intermediates of Formula IX (S)-{2-Hydroxy-ethyl)-pyirolidine-2-carboxylic acid tert-butyl ester L-Pyrrohdine-2-carboxylic acid to-i-butyl ester (0.41 g, 2.4 nimol) was dissolved in DMF (2 mL) containing diisopropylethylamine (1.25 mL, 7.2 mmol). A solution of 2-bromo-ethanol (0.34 mL, 4.8 mmol) in DMF (1 mL) was added. The reaction niixture was stirred at 70°C for 16 h. The solvent was removed in vacuo. EtOAc (20 mL) and saturated sodium bicarbonate solution (10 mL) was added. The aqueous phase was extracted twice with EtOAc (20 mL). The combined EtOAc phases were dried over magnesium sulfate, filtered and the filtrate was evaporated in vacuo. The product was isolated as an oil. Yield: 0.37 g, 72%. The following intermediate was prepared in an analogous fashion: (S)-l-(2-Hydrox)>-propyl)-pyrrolidine-2-carboxyHc acid tert-butyl ester Preparation of Intermediates of Formula HI 2-(4- Chloro-phenox\>)'phenol The compound was synthesised as described by G,W. Yeager, D.N. Schissel. Synthesis 1995,2^-30. The following intennediates were prepared in an analogous fasliion: 2-(3,4-Difl.uoro-pbenoxy)-pheno! 2- (3-Fluoro-phenox)i)-phenol 2~f3-Ch loro-pheTtoxy)~phenol 2-(4-Methoxy-phenoxy)-phenol 3-Chloro-2-iodoanisole A solution of S-chloroanisole (1.753 g, 12.3 mmol) in THF (60 mL) was cooled to -95 °C. A solution of sec-BuLi in cyclohexaiie(1.3M, 9.5 mL, i2.4Tnmol) was added dropwise keeping the internal temperature below -90 °C. After Ih a solution of I2 (3.15 g, 12,4 mmol) in THF (5 mL) was added dropwise. The mixture was allowed to reach room temperature overnight. Diethylether (100 mL) was added. The organic layer was washed with IM aqueous NajSOs, H2O, brine and dried over Na2S04. The crude product was adsorbed onto silica gel. After purification by flash clTromatography using silica gel, eluting with heptanes/EtOAc, 98:2, the product was obtained as colorless crystals Yield : 2.19g, 66%. 4-Bromo-2-iodo-anisole 4-Bromo-anisole (4.417 g, 23.6 mmol) was dissolved in acetoniliile (200 mL) and placed under an argon atmosphere in the absence of light. lodobenzene diacetate (9.18 g, 28.5 mmol) was added followed by iodme (3.6 g, 14.2 mmol). The mixture was stirred for 16 hours at ambient temperature. The mixture was then poured into IM Ha2S203 (200 mL) and stirred until the solution was colom-less. The solution was then extracted with diethyl ether (3 x 100 mL). The combined- organic extracts were then washed with brine, dried with Na^SO^, filtered and evaporated to dryness. The crude product was filtered through a silica gel plug eluting with heptane/ ethyl acetate (3:1) (200 mL). The filtrate was concentrated and the residue was distilled usin^ a Kugelrohr apparatus collecting die compound at 75 "C, 0.01 rabar. Yield 4.092g, 55%, 5-Bi-oiuo-2-iodo-a}!isole 4-Bromo-2-methoxy-anihne (20 g, 99 mmol) was dissolved in water (695 mL) and concentrated sulphuric acid (113 mL). The solution was cooled to 0 "C and sodium nih-ite (7.5 g, 109 mmol) dissolved in water (32 mL) was added and stiired for 1 hour at 5-10 'C. Potassium iodide (21.4g, 129 mmol) dissolved in water (100 mL) was added slowly whilst the mixture was virgorously stirred. After addition, the mixture was allowed to warm to room temperature. Ethyl acetate was added and the phases were separated. The aqueous phase was extracted with ethyl acetetate (3 X). The combined organic phases were then washed with IM NaOH, IM Na2S203, IM HCl, IM saturated NaHCOs and brine. The separated organic phase was dried (MgS04), filtered and concentrated in vacuo. The product was purified by flash chromatography using silica gel and eluting with heptane/ethyl acetate 1:1. The product was identified from relevant fractions which were combined and concenfrated in vacuo. Yield: 24.12g, 78% 5 - Chloro-2-(3-fluoro-phenylsulfanyl)-phenol A dry round bottomed flask was charged with NaO^Bu (398 mg, 4.14 mmol), Cul (62 mg, 0.33 mmol), neocuproin (66 mg, 0.30 mmol), 3-fluoro-thiophenol (394 mg, 3.07 mmol) and 3-chloro~2~iodoamsole (698 mg, 2.60 mmol). The flask was evacuated and baclcfilled with Ar three times. Dry toluene (10 mL) was added and the mixture stirred at 105 °C overnight. The mixture was diluted with toluene (40 mL) and filtered through a pad of siHca gel and evaporated to dryness to give a quantitative yield of crude ]-Ckloro-2-(3-fiuoro-phenylsulfa}iyl)-3'methoxy~bemene. The material was dissolved in toluene (20 mL) and cooled to 0 °C. Neat BBra (0.38 mL, 4.02 mmol) was added dropwise and the mixture was allowed to reach room temperature overnight. The mixture was quenched by the addition of HjO / ice (80 mL) and diethyl ether (100 mL), The organic layer was washed with brine. After drying over Na2S04 the crude product was adsorbed onto silica gel. After flash cliromatography using sihca gel, eluiing with heptanes/EtOAc, 96:4 the title compound was obtained a5 a yellow oil Yield: 642 mg, 97% over two steps. '^-Ch!oro-I-(3-fJiioro-pheuylsulfa7iy!)~2'methoxybenzene A dry round bottomed flask was charged with KO'BU (1.903 g, 17.0 mmol), 5-chloro-2-iodoani3o]e (4.054 g, 15.1 mmol), Pd^dbas (144 mg, 0.16 mmol), DPEPhos (176 mg, 0.33 mmol) and 3-fluoro-thiophenol (1.903 g, 17.0 mmol). The flask was evacuated and backfilled with Ar tliree times. Dry toluene (SO mL) was added and the mixture stnred at 95 °C for 2 h. The mixture was filtered through a pad of siHca gel followed by adsorption onto silica gel. After purification by flash chromatography using siHca gel, elating with heptanes/EtOAc, 97:3, the title compoimd was obtained as a yellow oil (3.41 g, 85%). and tlie following compounds was prepared in an analogous fashion: 4-BromO'2-(S-fluoTO-phenylsulfanyl)-l-methoxy-benzene 5-BromO'2-(S-fluoro-ph enylsulfanyl)-l-methox^>~benzene 4-Phenyl-2-(S-fluoro--phenylsulfanyl)-l-methoxy-benzene 4'Cyano-2~(3-fluoro-phenylsulfanyl)-l-methoxy-benzene 5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenol A solution of 4-cliloro-l-(3-fluoro-phenylsulfanyl)-2-metlioxybenzene (3.12 g, 11.6 mmoi) in dry toluene (60 mL) was cooled to 0 "C. Neat BBrs (1.50 mL, 15.9 mmol) was added dropwise and liie mixture was allowed to reach room temperature overnight. The mixture was quenched by the addition of H2O / ice (50 niL) and diethyl ether (50 mL). The aqueous layer was extracted with diethylether (2x 50 mL). The combined organic layers were washed with brine, dried over Na2S04 and adsorbed onto silica gel. After flash chromatography using siUca gel, eluting with heptanes/EtOAc, 95:5, the title compound was obtained as a Ught yellow oil (2.26 g, 77%). The following phenols were prepared in an analogous fashion: 2-Chloro-6- (3 -fluoro-phenylsulfanyl) -phenol 4-ChlorO'2-(3-fluoro-phenylsulfanyl)~phenol 4'Bromo-2-($-fliioro-phenylsulfavyl)'phenol 5'Bromo-2-(3-fluoro-phenylsiilfanyl)'pheiw} 4-Phenyl-2-(3-fluoi-o-phenylsulfanyl)-phenol ■?- Cyan o-2'(3-flu oiv-p/i e/iylsulfanylj-pheno/ Preparation of Intermediates V for Example 2 2-(2-Iodo-benzyl)-malonic acid diethyl ester Sodium (0.19 g, 8.2 mmol) was dissolved in absolute ethanol (12 mL). The solution was cooled on an ice bath, Malonic acid diethyl ester (1.3 g, 8.1 niniol) was added. A solution of 1-chloromethyl-2-iodo-benzene (2.0 g, 7.9 mmol) in absolute ethanol (6 mL) cooled on an ice bath was added to the malonic acid diethyl ester solution. The solution, which deposited sodium chloride, was let stand at 0 °C for 4 h and at room temperature overnight. The solution was neutralised with HCI (4N). The solvent was removed in vacuo and the residue was dissolved in dichloromethane (25 mL). Water (15 mL) was added and the phases were separated. The aqueous phase was reextracted with dichloromethane (10 niL). The combined organic fractions were dried (Na2S04), filtered and evaporated. Yield: 2.86 g, 92%. 3-(2-Iodo-phenyl)-propionic acid Concentrated HCI (2.3 mL) and water (0.3 mL) was added to 2-(2-iodo-benzyl)-malonic acid diethyl ester (1.4 g, 3.6 mmol) and the mixture was refiuxed overnight. Starting material could still be seen on TLC. More concentrated HCI (2 mL) was added and the mixture was refiuxed overnight. Water (20 mL) and ether (50 mL) was added to the mixture. The two phases was separated. The organic phase was extracted with an ammonium hydroxide solution (5N, 30 mL). The basic water phase was added slowly to ice-cold cone. HCI. The white precipitate was filtered and w^hed with ice-cold water and the solvent was removed in vacuo. Yield: 0.32 g, 32%. 3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propionicacid 3-(2-rodo-phenyl)-propionic acid (0.3 g, 1.1 mmol) was dissolved in water (2.8 mL). 3-Fluoro-benzenethiol (0.13 g, 0,99 mmol), KOH (0,15 g, 2.6 mmol) and Cu (13 mg, 0.2 mmol) was added. The mixture was refluxed overnight. The hot solution was filtered and the filtrate was made acidic with concentrated HCl. The mixture was extracted -with dichloromethane (2 x 25 mL). The combined organic phases were washed with water (15 mL), dried (MgSO^l, filtered and evaporated. Yield: 0.26 g. 96 %. 3 -[2-(3-Fluoro~ph enylsulfanyl)-phenyl]-propan-l-ol LiAlH4 (46 mg, 1.22 mmol) was suspended in ether (1.7 mL). A solution of 3-[2-(3-fluoro-phenylsulfanyl)-phenyl]-prop!omc acid (2.6 g, 0.94 mmol) in ether (1.7 mL) was added slowly. The reaction was stirred for 4 h at room temperature. Excess LiAIELi was hydrolysed with water. The mixture was made acidic using HCl (4N). Ether (20 mL) was added. The two phases were separated and the organic phase was washed with NaOH (2N) and then with water. The organic phase was dried (MgS04), filtered and evaporated. Yield: 0.14 g, 55%. l-(3-Iodo~propyl)-2-(3-fluro-phenylsulfanyl)-benzene Polymerbound PPhs (0.49 g, 0.46 mmol) was suspended in dichloromethane (4.5 mL). Imidazole (0.03 g, 0.46 minol) and I2 (0.12 g, 0.46 mmol) was added and the mixture was stirred for 5 minutes. A solution of 3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propan-1-ol (0.096 g, 0.37 mmol) in dichloromethane (0.5 mL) was added and the mixture was stirred for 4 h at room temperature. The resin was filtered off and washed with dichloromethane (2 mL). The filtrate was washed with Na2S203 (2X 2 mL) and water (2 niL). The organic phase was dried (MgS04), filtered and evaporated. Yield: 0.096 g, 71%. 2-[3-(3--Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethanol 3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-ol (2.65 g, 8.94 mmol) and potassium carbonate (2.113 g, 15.3 mmol) was dissolved in DMF (30 mL). Ethylene carbonate (1.601 g, 18.2 mmol) was added and the reaction was heated at 100 °C for 150 minutes. The solution was allowed to cool before the solution was carefully potured into 2M HCl (50 mL). The product was exfiracted with diethyl ether (50 mL). The separated organic phase was washed witli water (4 X 50 mL), 4% aq. MgSO^, brine and then the separated organic phase was dried (MgS04). The title product was isolated after concentration m vacuo. Yield: 2.96g , 97% Preparation of Intermediate of Formula VI for Example 4 (S)-l-[2-(5-Chloro-2-iodo-phenoxy)-ethyl]-pyrrolidine-2-carboxylic acid lert-butyl ester 5-Chioro-2-iodophenol (801 mg, 3.15 mmol) and PPha (1.15 %, 4.41 mmol) were dissolved in THF (25 mL). DIAD (0,91 mL, 4.62 mmol). was added dropwise and the solution was stirred for 20 min. A solution of l-(2-hydroxy-ethyl)-pyrrolidine-2-(5)-carboxylic acid tert butyl ester (816 mg, 3.79 mmol) in THF (4 mL) was added via canulation. The mixture was stirred for 40 min at 0 °C then for 1.5 h at room temperature and finally for 3 h at 50 "C. The mixture was diluted with heptanes (100 mL), washed with water (4x 25 mL), dried over Na2S04 and evaporated onto silica gel. After flash chromatography using silica gel, eluting with heptanes/EtOAc, 9:1, the title compound was obtained as a colorless oil (1.023 g, 72%). And the following intermediate was prepared in an analogous fashion: (S)-l-[2'(3-lado-biphenyl-4-yloxy)-ethylJ-pyrrolidme-2-carbox)ilic acid tert-butyl ester Preparation of Intermediates of Formula XII 3-Iodo-biph enyl-4-ol Biphenyl-4-ol( (5.26 g, 30.9 mmol), sodium iodide (4.635 g, 30.9 mmol), sodium hydroxide (1.276 g, 31.9 mmol) was dissolved in methanol ( 85 mL) and cooled to 0°C. To the solution was added 12% (w/v) sodium hypochlorite (20 mL) dropwise maintaining the temperature below 4 °C. The solution was stirred at this temperature for 1 hour and then 2M sodium thiosulfite (50 mL) wad added and the pH of the solution was adjusted to >pH 7 with IM HCl. The mixture was filtered and the filtrate was washed with water. The sohd was dried in a vacuum oven and then the title product was obtained as crystals after recrystallisation from heptane. Yield 7.0Sg, 77%. Preparation of Intermediates of Formula I used in preparation of example? 5-5f, 6 and 6b (S)-!-{2-['^-Bromo-2-(3-fluoro-phenylsiilfanyl)-phenox\!]-ethyl}-pyrrolidine-2-carboxylic acid ten-butyl ester 4-Bromo-2-(3-fluoro-phenylsulfanyl)-pheaoI (2.S98 g, 9.69 mmol) and triphen3'lphosphme (3.558 g, 13.6 mmol) was dissolved in tetrahydro&ran (70 mL) and cooled to 0°C under an inert atmosphere. To the solution was added DEAD (2.81 niL, 14.27 niinol)dropwise. After 25 minutes was added l-(2-hydroxy-ethyl)-pyrrohdine-2-(5)-carboxylic acid iert butyl ester (2.504 g, 1.163 mmol) in THF (15 mL) via carmulation. The mixture was stirred at room temperature for 16 hours. Heptane (350 mL) andTHF (lOOmL) was added. The organic phase was then washed with water (4 x 50 mL) and then brine, dried (Na2S04), filetered and the filtrate concentrated in the presence of silica gel. The crude products absorbed onto silica gel and elutedwith a gradient of heptane-heptane ethyl acetate (85:15). The product was isolated after concentration of relevant fi-actions. Yield: 3.342 g, 69% And the foUowmg intermediate was prepared in an analogous fashion: (S)-l-{2-[5-Bromo-2-(3-fluorO'phenylsulfanyl)'phenoyp^]'ethyl}-pyrrolidine-2-carboxylic acid tert-butyl ester Preparation of compounds of the invention Example 1 laa (S)-I-{2-[2~(4-Fluoro-phenylsulfanyl)'-phenoxy]-ethyl}-pyiTolidine'2-carboxylic acid A solution of L-l-(2-Hydroxy-ethyi)-p\'n-olidine-2-carboxyhc acid tert-butjd ester (0.068 mniol) in THF (0.5 mL) was added to polymerbound PPIIB (75 mg, O.OVmmol). A solution of 2-(3-Fluoro-phenylsulfanyl)-phenol (0.04 mmol) in THF (0.5 mL) and a solution ol'DEAD (0.06S mmol) in TITF (0.5 mL) added- The reaction was stitxed at room temperature for 16 h. The resin was filtered off and washed with methanol (2 x 1 niL) and THF (1 mL). The solvents were remo-\'ed by evaporation in vacuo. HCl in acetic acid (1 M, L5 mL) was added and the mixture was stirred for 16 h. The solvent \^'as removed in vacuo. The crude product was purified by preparative LC-MS. LC/MS (m/z) 362.2 (MH^); RT = 1.97; purity (^JV, ELSD): 93%, 100%; yield: 7.5 mg. The following compounds were prepared in an analogous fasliion: lab (S)-}-{2-[2~(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid from (S)-l-(2'Hydroxy-ethyl)-pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 400.1 (MH^); RT = 2.45; purity (UV, ELSD): 96%, 100%; yield: 6.2 mg. lac(S)-l'{2~[2~(4'Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid from (S)-l-(2-Hydroxy-ethyl)-pyrroUdine-2~carboxyhc acid tert-butyl ester LC/MS (m/z) 412.0 (MH^; RT = 2.21; purity {XJV, ELSD): 99%, 100%; yield; 5.5 rag. lad(S)- l-{2'[2'(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-py}rolidine-2--carboxylic acid from (S)'l-(2'Hydroxy-ethyl)'pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 362.2 (MET); RT = 1.98; purity (UV, ELSD): 95%, 100%; yield: 4.8 mg. lae (S)-{2-[2-(4-Chloro-phenylsulfa7iyl)-phenoxy]~ethyl}-pyrrolidme-2-carboxylic acid from (S)-l-{2-Hydroxy-ethyl)'pyrrolidi}m-2-carboxylic acid tert-butyl ester LC/MS (m/z) 378.1 (h'^); RT = 2.12; purity (UV, ELSD): 93%, 100%; yield: S.lmg. laf(S)-l- {2-[2-(3-Chloro-p!ieJiylsulfanyl) ■phe}WX)>]-ethyl)-pyrrolidine-2-carboxylic acid from (S)-l-(2-Hydroxy-ethyl)-pyiTolidine-2-carboxylic acid tert-butyl ester LGTMS (m,'z) 378.1 (MH^; RT = 2.10; purit>- (UV, ELSD): 98%, 100%; yield: 3.3mg. lag (S)-l-{2-[2-(3,4'Dichloro~phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2' carboxylic acid from (S)~l--(2-Hydroxy-ethyl)-pyrrolidine-2-carboxylic acid tert-butyl esterLCfM.^ (ra/z) 412.0 (MH^); RT = 2.28; purity (UV, ELSD): 99%, 100%; yield: 5.2mg. lah (S)-l-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyn-olidine-2~ carboxylic acid from (S)-l'(2-HydrQxy-ethyl)-p}>rrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 396.1 (MH^); RT = 2.15; purity (UV, ELSD): 98%, 100%; yield: 4.5mg. lai (S)-l-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2~carboxylicacid from (S)-l-(2-Hydroxy-ethyl)-pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 362.1 (MH^); RT = 2.02; purity (UV, ELSD): 9&'A, 100%; yield: 12.1mg. laj (S)-l'{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine'2-carboxylicacid from (S)-l~(2-Hydroxy-ethyl)-pyiTolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 362.2 (MH^); RT = 2.12; purity (lA', ELSD): 95%, 99%; yield: 12.7mg, lak (S}-l--{2-[2-(4-Methoxy~phenoxy)-pheiwxy]-ethyJ}-pyrrolidi7ie~2'Carboxylic acid from (S)-l-(2-Hydrox)!-ethyl)-pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 358.0 (MH*); RT= 1.83; purity (\J\L, ELSD): 100%, 99%; yield: I3.8mg. lal (S)-I-{2-[2~(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid from (S)-l-(2-Hydrox\!-ethyl)-pyrrolidine-2-carbox)'lic acid tert-butyl ester LC/MS (m/z) 364.2 (MiT); RT = 1,95; purity (UV', ELSD): 100%, 99%; yield: 13,8mg. lam I-{2(R/S)-[2-(4-Chloro-p'henoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid fi-om (S)-l-(2(R/S)-Hydroxrfi-propyl)-pyrrolidine-2-carboxyUc acid tert-butyl ester LC/MS (m/z) 376.1 (MH^; RT = 2.12; purity (UV, ELSD): 99%, 99%; yield: 4.1mg. Ian l-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}~pyrrolidine-2{Sy carboxylic acid fi-om L-l-(2(R/S)'Hydroxy'propyl)-pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 378.1 (ME^); RT = 2.07; purity (UV, ELSD): 96%, 99%; yield: 3.4mg. lao (S)-l-{2-[2-(3-Fluoro-phenoxy)-phenoxyJ-ethyl}-pyrrolidine~2-carboxylic acid fi-om (S)-l-(2-Hydroxy-ethyl}-pyrrolidine-2-carboxylic acid tert-butyl ester LC/MS (m/z) 346.2 (MH^; RT = 1.99; ptmty (ELSD): 95%.; yield: 3.44mg. lap l-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrroUdine-2(S)-carboxylic acid from L-l-(2(R/S)-Hydroxy-propyl)-pyrrolidine-2(S)'Carboxylic acid tert-butyl ester LC/MS (m/z) 360.3 (MH*); RT - 2.02; ptirity (UV, ELSD): 70%, 98%; yield: 7.2mg. laq l-{2(Il'S)-[2'(3-Fluora-phe}iylsulfa}iyl)-phenox)']-pTopyl}-pyrrolidine-2(S)~ carboxylic acid froml-(2(R/S)-Hydroxy-propyl}-pyrrQlidwe-2(S)-carboxylicacidte}-t-biitylester LC/MS (m^z) 376.1 (MIT): RT = 2,10; puritj' (U\^ ELSD): 99%, 9S%; yield: 4.3mg. hn- !-{2(R/S)-[2-f3-Chloro-phei!y!sidfa}iy!)'phenoxyJ-propyl/-pyrrolidwe-2(S)-carboxylic acid from l-(2(Ii'S)-HydToxy-pTopyl}-pyrrolidine-2(S)-carboxylic acid tert-butyl ester LC/MS (m/'2) 392.2 (MH^): RT = 2.23; purit>' (UV, ELSD): 94%, 88.9%; yield: 2.1mg, las ({2'[2-(4-tert'Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-aceticacid from [Ethyl-(2-hydi-oxy-ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/2) 388.2 (MH^); RT = 2.53; purity (UV, ELSD): 94%, 95%; yield: 5.6mg lot 2-{3~f2-(4-te}'t-Butyl-phenylsulfanyl)-phenoxy]-pyrroHdin~l -yl}-propionic acid from 2-(3-Hydroxy-pyrrolidin~l-yl)-propionic acid tert-butyl ester LC/MS (m/z) 400.0 (MH^); RT = 2.40; purity (UV, ELSD): 94%, 100%; yield: 4.2mg lau ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]'ethyl}-N—methyl-amino)-aceticacid from f{2-Hydroxy-ethyl)-methyI-aminoJ~acetic acid tert-butyl ester LC/MS (m/z) 351.9 (MH*); RT = 2.02; purity (UV, ELSD): 98%, 100%; yield: 9.9mg lav({2'[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl~amino)- acetic acid from [(2-Hydroxy-ethyl)-methyl-amino]-acetic acid tert-butyl ester LC/MS (m/z) 370.0 (MH^; RT = 2.07; purity (UV, ELSD): 93%, 100%; yield: 6.7mg law {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxymethyl]'pipe}'idin-l-yl}-acetic acid from (2'Hydroxymethyl-piperidin-l-yl)-acetic acid tert-butyl ester LC/MS (m/z) 414.4 (MIT^; RT 2.52= ; purity (UV, ELSD): 100%, 100%; yield: 2.6mg lax({2-f2-(3-Fluoro-phenyisulfanyl}-phenoxy]-ethyl}-N-methyl-amino)-acetic acid from [(2-Hydroxy-ethy!)-methyl-aminoJ-acetic acid tert-butyl ester LC'?4S (m'z) 336,2 (MIT); RT = 1.96; purity (UA^ ELSD): 96%, 95%; yield: 1.8mg lay {4-[2-(4-ter!-Butyl-phenylsu!fanyl)-phenoxy]-piperidm-l-yl}-acetic acid from (4-Hydroxy-piperidin-l-yI)-acelic acid tert-butyl ester LC/MS (m/z) 400.0 (MH^); RT = 2.48; purity (UV, ELSD): 89%, 100%; yield: 5.5mg laz (N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]~ethyl}'ami-no)- acetic acid from [(2-Hydroxy-ethyl)-isopropyl-amino]-acetic acid ten-butyl ester LC/MS (m/z) 414.2 (MH^; RT = 2.26; purity (UV, ELSD): 95%, 100%; yield: 2.4mg Iba ({2-[3-(3,4-Dichloro-phenylsu!fanyl)-phenoxy]-ethyl}-N-ethyl-ainino)-acetic acid from [Ethyl-(2-hydroxy-ethylf amino]-acetic acid tert-butyl ester LC/MS (m/z) 400.1 (MH^); RT = 2.27; purity (UV, ELSD): 99%, 100%; yield; 8.3mg Ibb P^-Ethyl-(2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}'amino}~acetic acid from [Ethyl-(2-hydroxy-ethyl)-amino]'acetic acid tert-butyl ester LC/MS (m/z) 378.3 (MH*); RT = 2.13; purity (UV, ELSD): 99%, 100%; yield: 8.5mg lbc2-{3-[2--(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-J-yl}-propionic acid from 2-(3-Hydroxy-pyrrolidin-l-yl)-propionic acid tert-butyl ester LC/MS (m/z) 412.0 (Mif); RT = 2.25; purity (UV, ELSD): 100%, 100%; yield: 7.5ing lbd(S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin'l-yl}-aceticacid from (R)'(3-Hydroxy-pyrrolidin-I-yl)-acetic acid tert-butyl ester LC/MS (m/z) 386.0 (MH^); RT = 2.42; purity (UV, ELSD): 90%, 95%; yield: 2.2mg Ibe ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid fi-om [Ethyl-(2-hydrox}!~ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 384,2 (MlT); RT = 2.15; purit>' (L^V, ELSD): 97%, 100%; yield; S.2mg 1 bf (N-2-propyl- {2-[2-(4-methylsulfanyl-phenylsulfanylj-phen oxy]-ethyl}-amino) - acetic acid from [(2-Hydroxy'efhy!j-isopropyl-aimno]-acettc acid terl-bvtyl ester LC/MS (m/'z) 392.2 (MH*"); RT = 2.17; purity (UV, ELSD): 97%, 99%; yield: 9.9mg Ibg {3-[2-(4-tert-Butyl-ph.enylsulfanyl)-phenoxy]^pyrrolidiii-I-yl}-acetic acid from (3-Hydroxy-pyrrolidin-l-yl)-acetic acid tert-butyl ester LC/MS (m/z) 386.0 (MH'); RT = 2.38; purity (UV, ELSD): 96%, 100%; yield: 3.1mg Ibh ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N'ethyl-amino)-aceticacid from [Etkyl-(2-hydroxy-ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 366.2 (MH"); RT = 2.10; purity (UV, ELSD): 100%, 100%; yield: ll.Smg Ibi ((2-[2-(4~Chloro-phenylsulfanyl)-phenoxy]-ethyl-}N'methyl-amino)-acetic acid from [(2-Hydroxy-ethyl)-methyl-amino]-acetic acid tert-butyl ester • LC/MS (m/z) 352.2 (MH^); RT = 2.12; purity (UV, ELSD): 78%, 97%; yield: 2.2mg Ibj {4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-l-yl}-acetic acid from (4-Hydroxy-pipeHdin-l-yl)-acetic acid tert-butyl ester LC/MS (m/2) 412.1 (MH^; RT = 2.32; purity (UV, ELSD): 99%, 100%; yield: 5,9mg lbk2-{3'[2-(4-Trifluorometkyl-phenylsulfanyl)~phenoxy]-pyrrolidin'l-yl)-propionic acid fi-om 2-(3-Hydroxy-pyrrolidin-l-yl)-propionic acid tert-butyl ester LC/MS (m/z) 412.1 (MH^); RT = 2.17; purity (UV, ELSD): 99%, 100%; yield: 6,lmg ) lbl({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid from [(2-Hydroxy-ethyl)-isopropyl-amino]-acetic acid tert-butyl ester LC/MS (m/2) 402.2 (MH"); RT = 2.57; purity (UV, ELSD): 90%, 98%; yield: S.3mg Ibm ({2-f2-(4-iert-BiiTy!-phenyIsuIfany'!)-phenoxy]-ethy!}-N-}nethyl-amino)-acetic acid from [f2-Hydroxy-ethyl)'methyl-amino]-acetic acid tert-buty! ester LCMS (m/z) 373.8 (MH'); RT = 234; purity (UV, ELSD): 91%, 100%; yield: 8.9mg Ibn (2-[2~(4-Methylsidfanyl-phe}iylsulfanyl)-phe}Wxymethyl]-piperidm-l-yl}-aceti.c acid from (2-Hydroxymethyl-piperidin-l-yl)-acetic acid tert-buly} ester LC/MS (m/z) 404.2 (MH+); RT = 2.21; purity (UV, ELSD): 9S%, 100%; yield: 2.6nig Iho ({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid from [(2-Hydroxy-ethyl)-methyl-amino]-acetic acid tert-buty! ester LC/MS (m/z) 385.8 (MET); RT = 2.19; purity (UV, ELSD): 95%, 100%; yield: S.lmg Jbp (N-MethyI-{2-[2~{4-trifluo}'omethyl-phenylsulfa}iyl)~-phenoxy]-ethyl}--amino)- acetic acid from [(2--Hydroxy-ethyl)'methyl~amino]-acetic acid tert-butyl ester LC/MS (m/z) 386.0 (MIT'); RT = 2,13; purity (UV, ELSD): 95%, 100%; yield: 5.3mg lbq-2-{3(R)-[2-(4'tert-Biityl'phenylsulfanyl)'phenoxy]~pyrrolidin-l-yl}-propionic acid from (S)~2-(3-Hydroxy-pyrrolidin-l-yl)'propionic acid tert-butyl ester LC/MS (m/z) 400.1 (MH^; RT = 2.44; purity (UV, ELSD): 97%, 100%; yield: 9.2mg lbr2-(3(R)'[2-(3.4-J2>ichloro-phenylsulftinyl)'phenoxy]-pyn-olidin-}-yl}-propionic acid from (S)-2-(3'Hydroxy-pyjrolidin~J-yl)'propionic acid tert-butyl ester LC/MS (m/z) 412.1 (MH^); RT = 2.26; purity OJV, ELSD): 100%, 98%; yield: 9.4mg lbs 2-[3fR)-f2-(4-methylphenyl)-sulfanyI'pheTiox)0-pyyrolidin-I-yl]-propiomc acid from (S)-2-(3-Hydroxy-pyrrolidin-l-yl)-propionic acid tert-butyl ester LC/MS (nVz) 358.2 (MH^); RT = 2.06; purity (IJV, ELSD): 9S%, 98%; yield: S.lmg lbt{3(R)'[2-{4-terf.-Butyl'pheuyisu!fanyl)-pheiwx)']-pyr roUdin-l-yl}-acetic acid from (S)-(3-Hydroxy-pyn-o!idin-!-ylfaceitc acid ten-butyl ester LC/MS (i-n/z) 386.2 (MH^); RT = 2,38; purity (UV, ELSD): 94%, 99%; yield: 3.0mg Ibu 2-{3(R)-[2-(4~Trifluoromethyl-phenylsidfa}iyl)-phenoxy]-pyrrolidin-I-yl}- propionic acid from (S)-2-(3-Hydroxy-pyrroLidin-I-yl)~propionic acid tert-butyl ester LC/MS (m/z) 412.2 (MH^); RT = 2.20; purity (UV, ELSD): 98%), 100%; yield: 9.5mg Ibv 2-{3(R)-[2-(4-Chloro-phenylsulfanyl)~phenoxy]-pyrrolidin-l-yl}-propionic acid from (S)-2-(3-Hydroxy-pyrrolidin-l-yl)-propionic acid tert-butyl ester LC/MS (m/z) 378.1 (MKT); RT = 2,13; purity (UV, ELSD): 91%, 100%,; yield: 6.3mg Ibw ({I'[2-(3-Chloro-phenylsulfanyl)-phenoxymethyl]'propyl}-N-ethyl-amino)-acetic acid from [Ethyl-(l-hydroxyinethyl-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 394.2 (MH^); RT = 2.29; purity (UV, ELSD): 97%, 99%; yield: 4.8mg Ibx ({l-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy)'butan-2-yl}-N-ethyl-amino)-acetic acid from [Ethyl-(l-hydroxyrnethyl-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 428.1 (MH*); RT = 2,46; purity (UV, ELSD): 94%, 100%; yield: 4.6mg Iby ({l-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-aminoj-acetic acid from [Ethyl-(l-hydroxymethyl-2-methyl-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 442.2 (MlT); RT = 2.56; purity (UV, ELSD): 96%, 100%; yield: l.Omg lbz({}-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butmu2-yl}-N-ethyl-amino)' acetic acid from [Ethyl-(}-hydroxym.ethyl-propyl}-amino]-acetic acid tert-butyl ester LC/MS (nvz) 412.1 (IvIH^V RT = 2,32: puritj' (LY, ELSD): 99%, 100%; yield: 4.7mg lea ({l-[l-(3-Chloro-phenyhuIfanyl)-pheHOxy]-propan'2-yl}-M-ethyl-amiiw)'-acetic acid from [Ethyl-(2-hydroxy:-l--methyl-ethyl)-amino]-acetic acid tert-buty] ester LC/MS (m'z) 380.1 (MiT); RT = 2.18; purity (}J\\ ELSD): 99%, 100%; yield: 4.8mg Icb ({l-[2-(3-Chloro-4-fliioro-phenylsulfanyl)-phenoxy]'butan-4-methyl'2-yl)}'-N-ethyl-amino)-acetic acid from [Ethyl-(}-hydroxyf}iethyl-2-methyl-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 426.2 (MH^); RT = 2.42; purity (UV, ELSD): 90%, 100%; yield: 0.9mg Ice ({l-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)- acetic acid from [Ethyl-(2-hydroxy-l-meihyl-ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 398.2 (MJf); RT = 2.12; purity (UV, ELSD): 96%, 100%; yield: 3.1mg led (S)-{I-[2-(3-Chloro-phenylsulfanyl)-pkenoxy]-propan-2-yl}-N-metkyl-amino)-acetic acid from (S)-[(2-Hydroxy-l-methyl-ethyl)-methyl-amino]'acetic acid tert-butyl ester LC/MS (m/z) 366.2 (MH^; RT = 2.08; purity (UV, ELSD): 98%, 97%; yield: 4.4mg Ice (S)-({l-[2-(3-Chloro-phenylsulfanyl)-phenoxyJ'propan'2-yl)-N-eihyl'amino)-acetic acid from (S)-[Ethyl-(2-hydroxy-l-methyl-ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 380.2 (Mif); RT = 2.18; purity (UV, ELSD): 72%, 100%; yield: 1.3mg lcf({l-[2-(3,4-Dichloro-phenylsulfanyl)'phenoxy]'propan-2-yl}-N-eth.yl--amino)- acetic acid from [Ethyl-(2-hydroxy-l-methyl'ethyl)-amino]-acetic acid tert-butyl ester LCMS (m/z) 416.2 (MH^); RT = 2.34; punty (U\^ ELSD): 100%, 100%; yield: 4.9mg leg ('{i'[2-(4-ChlorO'phenyisulfanyl)-phenox}']~p7-opan-2-yl}-N-ethyl-a7nino)-acet-ic acid from [Ethyl-(2-hydroyy-l-melhyheihyl)-m7imo]-acetic acid tert-butyl ester LC/MS (m/z) 380.3 (MH^); RT = 2.19; puiity (UV, ELSD): 94%, 100%; yield: 3.9mg Ich ({I-[2-(3-Chloro-phe}iylsulfanyl)~phenoxymethyl]-propyl}-N-methyl-amino)- acetic acid fi-om [(l-Hydroxymethyl-propyl)-methyl-amino]-acetic acid tert-butyl ester LC/MS (m/z) 380.2 (MH*); RT = 2.21; purity (UV, ELSD): 98%, 100%; yield: 3.6mg lei ((l-[2-(4'ChlorO'phenylsulfanyl)'phenoxymethyl]-propyl}-N-ethyl-amino)~acetic acid from [Ethyl-(l-hydroxymeihyl-propyT)-amino]-acetic acid tert-butyl ester LC/MS (m/2) 394.3 (MH^); RT = 2.33; purity (UV, ELSD): 96%, 100%; yieJd: 4.5mg Icj (N-Ethyi-{l~[2-(3-fluoro-phenylsuifanyl)-phenoxymethyl]-propyI}-amino)-acetic acid from [Ethyl-O-hydroxymethyl-propylj-aminoJ-acetic acid tert-butyl ester LC/MS (m/z) 378.3 (MH"); RT = 2.16; purity (UV, ELSD): 99%, 100%; yield: 5.7mg lck(R)-({2--f2-(3,4-Dichioro-phenylsulfanyl)-phenoxy]-l-methyl-ethyl}-N-ethyl-amino)'acetic acid from (R)-[Ethyl-(2-hydroxy-l-methyl'ethyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 416.0 (Mif); RT = 2.35; purity (UV, ELSD): 92%, 100%; yield: 1.5mg lcl(S)--(2{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-acetic acid from (S)-[(2~Hydroxy-2~methyl-ethyl)-metkyl-amino]-acetic acid tert-butyl ester LC/MS (m/z) 350.1 (MH""); RT = 2.00; purity (UV, ELSD): 96%, 97%; yield: 2.6mg 1cm (Rj-(2{2-[2-(3-Chloro-phenylsulfany[)-phenoxyJ-}-propyl~N-methyl-amino)-acetic acid from (R)-ff2-Hydroxy-l-mathyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester LC/MS fm/z) 366.1 (^ffl^); RT = 2.10; puritj' (LA', ELSD): 9S%, 98%; ;aeld: 6.1mg Icii ({2-[2-(3-Fhioro-phenylsidfanyl)-p]mimxy]-propyl}-N-methyl-'ammo)-acetic acid from [(2-Hydroxy-propyl)-niethyi-amino]-acetic acid tert-butyl ester LC/MS (m/z) 350,1 (MH^); RT = 1.97; purity (UV. ELSD): Sl%, 99%; yield; 2.2mg Ico f{2-[2-(3-Chloro-phenylsulfany!)-phe!Wxy]-propan-Iyl}'N-ethy!-amiT}o)-acetic acid fi-om [Ethyl-(2-hydroxy-propyl)-ainino]-acetic acid tert-butyl ester LC/MS (m/z) 380.3 (MfT); RT= 2.19; purity (UV, ELSD): 97%, 9^%; yield: 2.9mg Icp ({I'[2~(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl-amino)-acetic acid fi-om [(!-Hydroxymethyl-2-methyl-propyl)-methyl-amino]-acetic acid tert-butyl ester LC/MS (m/z) 394.2 (MH"); RT = 2.31; purity (UV, ELSD): 93%, 100%; yield: 2.3mg Icq ({3-methyl-l-[2-(4-trifluoromethyl-ph.enylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-aminoj-acetic acid from [Ethyl-(l-hydroxymethyl-2-methyl-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 442.3 (MH^; RT = 2.46; purity (UV, ELSD): 9E%, 100%; yield: 1.7mg Icr ({I-[2-(3-Chloro-4~fluoro~phenylsulfanyl)-phenoxy]-butan-2-yl}-N-meihyl-amino)-acetic acid from [(I-Hydroxymethyl-propyl}-methyi-aminoJ-acetic acid tert-butyl ester LC/MS (m/z) 398.1 (MH"); RT = 2.24; purity (UV, ELSD): 96%, 98%; yield: S.lmg Ics (S)-(l{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}N-methyl-amir)o)-acetic acid from (S)-[(2-Hydroxy-l-methyl-ethyl)-methyl-amino]-acetic acid tert-but}'l ester LC/MS (m/z) 3S4,I (MET); RT = 2.16; purity (UV, ELSD): 97%, 100%; yield: 3.7mg lct(S)-(2-{2-[2-(3-FluorO'phenylsulfanyl)~phenoxy]-propyl}-N-methyl-amino)-acetic acid from (S)-[(2-Hydroxy-l-methyl-ethyl)-methyl-ami.no]-acetic acid tert-butyl ester LGMS (ni'z) 350.1 (IvlH^): RT = 1.97; purity (U\', ELSD): 91%, 97%; yield: 5.5mg Icii {{l-[2-{4-t.ert--Bvtyl-phe}iylsulfanyl)~phenox))]-3'methyl-b-i{tan-2'-yl}-N-ethyl-amino)-acetic acid from [Ethyl-(1-hydroxyfnethyl-2-methyl-propyl)-amino]-acetic acid tert-butyl ester LCMS (m/2) 430.2 (MH^); RT = 2.73; purity (UV, ELSD): S3%, 100%; yield: l.Omg lev (S)-({l-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid from (S)-[(2-Hydroxy-l-methyl-ethyl}-methyl-amino]-acetic acid teii-butyl ester LC/MS (ni/z) 400.0 (MH^); RT = 2.27; purity (UV, ELSD): 100%, 98%; yield: 3.5mg lew ({}-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxyJ'3-methyl-buta7t-2-y!)-N-methyl-amino)-acetic acid frojJi [(]-Hydroxymethyl-2-methyl-propyl)--methyl-ami}]o]-acetic acid tert-butyl ester LC/MS (m/z) 412.0 (MH""); RT = 2,35; purity (UV, ELSD): 87%, 97%; yield: 3.0mg lex ({l-[2-(4-tert-Butyl-phenylsulfanyl)-phenox)']-3--methyl-propan-2-yl}-N-ethyl-amirio)-acetic acid from [Ethyl-(2-hydroxy'l-methyl-ethyl)-amino]-acetic acid teH-butyl ester LC/MS (m/z) 402.2 (MHT'); RT = 2.53; purity (UV, ELSD): 90%, 99%; yield: 3.4mg ley ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-l-yl}-N'ethyl~ aminoj-acetic acid from [Ethyl-(2-hydroxy-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 398.1 (MiO; RT = 2.24; purity (UV, ELSD): 86%, 96%; yield: 2.3mg Icz ({2-[2-(4-methoxy-phenylsulfa}jyl)-phe7ioxy]-propan-]-yl}- N-Cyclohexyl - amino)-acetic acid from [Cyclohex}>l-(2-hydroxy-propyl)-amino]-acetic acid lert-butyl ester LCMS (m/2) 430.3 (MtT); RT = 2.32; purity (LA', ELSD): 83%, 80%; yield: 1.5mg Ida { [2-(2-{4-methylsulfanyl-phenox}')-pj-opan-l-yl-]-N'Cyclohexyl-amino}--acetic acid fi-om [Cyclohexyl~(2-hydroxy-propyl)-amino]-acetic acid tert-butyl ester LC/MS (m/2) 414,4 OvIH^): RT = 2.50; purity (m, ELSD): 79%, 100%; yield: l.lmg Idb ({2-[2'(3-Chloro-phenylsulfanyl.)phenox)>]-propan-!-yI}-N-cyclohex)>i'amino}-acetic acid from [CyclohexyI-(2-hydroxy-pj-opyl)-amino]-acetic acid tert-butyl ester LC/MS (m/z) 434.9 (MH""); RT = 2.50; purity (UV, ELSD): 98%, 84%; yield: 2.1mg Example 2 (S)-]-(3-[2-{3-Fluoro-phenylsulfa}iyl)phenyl]-propyl}-pyrrolidine-2-carboxylic acid hydrochloride l-(3--Iodo-propyl)-2-(3-fluro-phenylsulfanyl)-ben2ene (4S mg, 0.13 mmol) was dissolved in DMF (0.4 mL). S-PyrroUdiiie-2-carboxylic acid (er^-butyl ester (22 mg, 0.13 mmol) and diisopropylethylamiwe (25 j^L, 0.14 mmol) were added. The mixture was stirred at 50 °C for 6 h and then at room temperature ovemight. The solvent was removed in vacuo. The residue was dissolved in HCl/AcOH (3.1 mL) and stirred ovemight. The solvent was removed in vacuo. The crude product was purified by prepai-ative LC-MS. Yield: 16.2mg, 34% LC/MS (m/z) 360.3 (Mlf); RT = 2.18; purity (UV, ELSD): 89%, 100% 2b (S)-2~({2'[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]~ethyl}-methyl-amino)-propionic acid hydrochloride 2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethanol (0.493 mg, 1,45 mmol) was dissolved in dicliloromethane, cooled to -78°C and placed under an inert atmosphere. To the solution was added N-ethyldiisopropylamine (0.63 mL, 3.62 iTimol) aiid then triflic anhydride (0.32 mL, 1.90 mmol), dropwise. The solution was allowed to stir for 40 minutes and then warmed to room temperature. L-N-methyl-alanine tertbutyl ester (435 mg, 2,22 mniol) was added and the mixture was stirred for 16 hours. Silica gel was added to the mixmre and the solvent was removed m vacuo. The products were absorbed onto silica gel and then purified by flash ctu-omatography eluting with heptane/ethyl acetate (90:10). The intennediate butyl e.ster was isolated after evaporation of relevant fractions. Yield 403mg, 58% This was tlien dissolved in IM HCI/'AcOH (15niL) and stirred at room temperature for 16 hours. The soh'ent was then removed in vacuo to give the title compound as a wliite solid. Yield: 235 mg, 60% ^H NMR (DMSO, 500 MHz) 1.33 (d, 3H), 2,33 (s, IH), 2.64 (s, 3H), 3.35 (m, 2H), 4,1 (m, IH), 4.4 (m, 2H), 6.9 (m, 3H), 7.1-7.2 (m, 2H), 7,2 (m, 2H), 7.37 (m, 3H), 7.55 (m, IH) and the following compound was prepared in an analogous fashion 2c ({2-[3-(3-Fliioro-phenylsulfanyl)'biphenyl-4-yloxy]-ethyl}-methyl-amino)-acetic acid ff-om 2-[3-(3-Fluoro-phenylsuifanyl)-biphenyl'4-yloxy]-ethanol Yield: 282mg, 54% over two steps 'H NMR (CHCI3, 500 MHz) 2.45 (s, IH), 2,7 (s, 2H), 3.45 (m, 2H), 3.98 (s, 2H), 4,42 (m, 2H), 6.92 (m, 3H), 7.15 (m, 2H), 7.24 (m, 2H), 7.4 (dd, 3H), 7.55 (dd, IH) LC/MS (m/z) 412.5 (MH^; RT = 2.53; purity (UV, ELSD): 95.1%, 99.6% Example 3 371 (S)'I-{2-[4-Chloro-2-(3-fluoro-phenylsulfaTiyl)'-phenoxy]-eihyl}-pyrrolidine-2-carhoxylic acid hydrochloride A solution of 4-Chloro-2-(3-fluoro-phenyisulfany!)-phenol (290 mg, 1.14 mmol), PPh, (398 mg, 1.52 mmol) in dr>' THF (6 mL) was cooled to 0 °C. DEAD (0.25 mL, 1.59 mmol) was added dropwise and the solution was stirred for 20 min. A solution of l-(2-liydroxy-ethyI)-pyrroHdine-2-(5)-carboxylic acid teii butyl ester (370 mg, 1.72 mmol) in THP (4 mL) was added ■\'ia canulation. The mixture was stirred for 40 min at 0 °C then for 1.5 h at room temperature and fmall;' for 3 b at 50 "C. The mixture was diluted with heptanes (100 mL), washed with water (4x 25 mL), dried over Na^SO^ and evaporated onto silica gel. After flash chromatography using silica gel, ■ eluting ^^'ith heptanes/EtOAc, 9:L the intermediate tert butyl ester was obtained as a colorless oil (393 mg, 76%). To a solution of the ester (380 mg, 0.84 mmol) in glacial HOAc (10 mL) was added HCl in HOAc (IM, 10 mL). The mixture was stirred at room temperature ovemiglit. The solution was e^'aporated to dryness to give the title compound as a colourless foam Yield: 367 mg, 100%. 'HNMR (CDCI3, 500 MHz) 2.01 (br, 2H), 2.19 (br, IH), 2.44 (br, IH), 3.21 (br, IH), 3.57 (br, IH), 3.94 (br, 2H), 4.42 (br, 2H), 4.67 (br, IH), 6.92-7.00 (m, 3H), 7.03-7.06 (m, IH), 7.11(br, IH), 7.21-7.25 (m, IH), 7.28-7.33 (m, IH). LC-MS (m/z) 396.0 (MH^); RT = 2.31; purity (UV, ELSD): 97.1%, 97.9%, The following compounds were prepared in an analogous fashion: 3b (S)-l-{2'[3-Chloro-2-(3-fluoro-phenylsuljunyl)-phenoxy]-ethyl}pynolidine-2- carboxylic acid hydrochloride from of3~ChlorO'2-(3-fluoro-phenylsulfanyl)-phenol Yield 452mg ■'HmiR. (CDCI3, 500 MHz) 1.86-1.94 (br, 2H), 2.18 (br, IH), 2.34 (br, IH), 3.11 (br, IH), 3.50 (br, IH), 3.74 (br, IH), 3.89 (br. IH), 4.39 (br, 2H), 4.65 (br, IH), 6.67 (d, IH), 6.76-6.79 (m, 2H), 6.98-7.00 (m, IH), 7.18-7.21 (m, 2H), 7.33-7.36 (m, IH). LC-MS (m/2) 396.1 (MH^); RT =2.21; purity (VV, ELSD); 95.1%, 98.7%.; 3c (S)-l-{2-[5-Chloro-2-(3~fluoro-phenylsulfanyl'hphenox)']-ethyl}pyrroiidine-2-carboxylic acid hydrochloride from of5-ChlorO'2-(3-fluoro-pheuylsulfanyl)'Dheno} Yield: 539 mg 'H NMR (CDCI3, 500 MHz) 2.01 (br, 2H), 2.21 (br, IH), 2.41 (br, IH), 3.19 (br, IH), 3,57 (br, IH), 3.90 (br, IH), 4.41 (br, 2H), 4.65 (br, 2H), 6.92-6.96 (m, 3H), 7.01-7,06 (m,2H), 7.14-7.29 (m,2H). LC-MS (nVz) 396,1 (MH^); RT = 2.28; purity (UV, ELSD); 93.7%, 99,9% yield 539 mg 3d (S)-l-{2-[4-CyanO'2-(3-Jluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid from 4-cyaj20'2-(3-fluorO'phenylsulfanyI)-phenoI Yield; 257 mg, 100% 'H NMR (CDCI3, 500 MHz) 1.82 (m, IH), 1.97 (m, 2H), 2.35 (m, IH), 3.13 (dd, IH), 3.3 (m, 2H), 3.68 (d, IH), 4.3 (t, IH), 4.5 (m, 2H), 7.2 (m, 2H), 7.3 (d, IH), 7.45 (m, IH), 7.55 (s, IH), 7.88 (d, IE) LC-MS (m/2) 387 (MH^); RT=1.98 ;purity (UV/ELSD) 98,4%, 91.7% Example 4 4a (S)'l-[2-(5-ChlorO'2-phe}iylsulfanyl'pheTioxy)-ethyl]pyrrolidine-2'Carboxylicacid hydrochloride A dry round bottomed Qask was charged with l-[2-(5-Chloro-2-iodo-phenoxy)-ethyl]- pyrrohdine-2-(S)-carboxyUc acid tert-butyl ester (301 mg, 0.666 mmol), toluene (4.5 mL), KO'Bu (100 mg, 0.89 mmol), thiophenol (78 mg, 0,708 mmol). The mixture was evacuated and baclcfilled with argon three times. A separate dry round-bottomed flask was charged with Pdjdbas (9.6 mg, 0,010 mmol) and DPEPhos (16 mg, 0.030 mmol), evacuated and backfilled with argon three times. Toluene (1.5 mL) was added and the mixture stirred at room temperature for 10 mill. 1.0 mL of the catalyst mixture was added to the reaction mixture "\'ia s\Tinge, and the reaction mixture was heated to 90 "^C for 3 h. The mixture was diluted with heptane (6 mL), filtered and adsorbed onto silica gel. After purification by flash chromatography using silica gel. eluting with heptane/EtOAc, 92:8, the teit-butyl ester was obtained as a yellow oil (209 mg, 72%). To a solution of the tert-butyl ester (200 mg) in glacial HOAc (10 mL) was added HCl in HOAc (IM, 10 mL). The mixture was stirred at room temperature overnight. The solution was evaporated to dryness to give the title compound as a colorless foam. Yield: 136ing, 54% 'H NMR (500 MHz, CDCI3) 2.05 (br, 2H), 2.27 (br, IH), 2.45 (br, IH), 3.24 (br, IH), 3.58 (br, IH), 3.95 (br, 2H), 4.43 (br, 2H), 4.66 (br, IH), 6.85-7.00 (m, 2H), 7.13 (br, IH), 7.26-7.38 (m, 5H). LC-MS (m/z) 377.9 (MH""); RT = 2.20 rain; purity (UV, ELSD): 99,9%, 96.4%;yield 136mg and the following compound was prepared in an analogous fashion 4b (S)-l-(2-[3~(3-Fluoro-phenylsulfanyl)-biphenyl~4'yloxy]-ethyl}'pyrrolidine-2-carboxylic acid hydrochloride from (S)-l-[2-(3-Iodo-biphenyl-4'yloxy)-ethyl]-pyrrolidine-2-carboxylic acid tert-butyl ester and 3-fluoro-thiophenol Yield 63mg, 13% ^H NMR (500 MHz, CDCI3) 1.82 (m, IH), 1.92 (m, IH), 2.15 (m, IH), 2.3 (m, IH), 3.02 (m, IH), 3.46 (brm, IH), 3.73 (m, IH), 3.S2 (m, IH), 4.1-4.4 (brm, 2H),4.65 (m, IH), 6.7 (dd, 2H), 6.85 (d, IH), 6.95 (m, IH), 7,1 (d, IH). 7.2 (m, IH), 7.26 (dd, IH), 7.32 (m, 2H), 7.4 (m, 2H) LC-MS (m/z) 438,5 (MH')i RT=2.51 ;purity (UV/ELSD) 94.0%, 99.3% Example 5 5a(S)-(2-[4'-Methoxy-3-{3-fluorO'phenylsulfanyl)-biphenyl~4-yloxy]-ethyl}-pyiTolidine-2-carboxyiic acid hydrochloride l-f2-[4-Bromo-2"(3-fluoro-pheny!si]lfanyl)-phenoxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid tert-butyl ester (387 mg, 0.78 mmol), 4-methoxyphenyl boronic acid (202 mg, 1.33 mmol) and K2CO3 (296 mg, 2.14 minol) was dissolved in dimetlioxyethane (6 mL) and w^ater (3 mL) and solution was degassed with nitrogen for 10 minutes. Bis(triphenylphosphine)palladium (II) chloride (29 mg, 0.041 minol) was added and the mixture was heated at 85 "C for 2 hours. The mixture was then cooled to room temperature and diluted with diethylether. The organic layer was separated and then washed with saturated aqueous sodium bicarbonate (10 mL) and then dried (hAgSO^). To the filtrate was added silica gel and tlie product was absorbed on to the silica gel during evaporation of the solvent in vacuo. The product was then purified by flash chromatography using a gradient of heptane/ethyl acetate 92:8 to heptane/ethyl acetate 85:15 on a Flashmaster sihca gel column. Concentration in vacuo of relevant fractions afforded the intermediate butyl ester. Yield. 300 mg, 73%. This was then dissolved in IM HCl/AcOH (lOmL) and the solution was stirred at room temperature for 16 hours. The solution was then evaporated to dryness and the product dried in a vacuum oven. Yield 299 mg, 104%. 'H NMR (500 MHz, CDCI3) 1.93 (br m, IH), 2.05 (br m, IH), 2.35-2.45 (br m, 2H), 3.11 (bim, IH), 3.5 (brm, IH), 3.8 (s, 3H), 3.9 (brm, 2H), 4.3 (brm, 1H),4,45 (br m, IH), 4.7 (br m, IH), 6.87 (m, 2H). 6.94 (m, 3H), 7.0 (br m, IH), 7.2 (br m, IH), 7.39 (d, 2H), 7.49 (m,lH), 7.55 (m, IH) LC-MS (m/z) 468.5 (MH^); RT = 2.51 min; purity (UV, ELSD): 86.9%, 98.4% and the following compounds were prepared in an analogous fashion Sh(S)-{2-[4'-Cyano-3-(3'jluoro-phenylsulfanyl)'biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid hydrochloride from (S)- I'{2--[4-Bromo-2-{3'fluoro~phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2'-carboxylic acid ten-butyl ester Yield; 274 mg 'n NMR (500 MHz, DMSO) 1.78 (m,lH), 1.95 (m. 2H), 2.28 (m, IH), 3.11 (dd, IH), 3.5 (m, 2H), 3.7 (d, IH), 4.38 (m, IH), 4.5 (m, 2H), 7.09 (m, 3H), 7.33 (d, IH), 7.4 (m, 2H), 7.7 (s, IH), 7.7-7.8 (m, 5H) LC-MS (m/z) 463 (MH^): RT=2.2 (UV,ELSD): 93.7%, 89.5% 5c (S)-}-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrroUdine-2-carboxylic acid hydrochloride from (S)'l~{2-[5-Bromo-2'(3-fluorO'-phenylsulfanyl)'phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid tert-biityl ester Yield: 285 mg, 56% over two steps 'H NMR {500 MHz, DMSO) I.S (m, IH), 2.0 (m, 2H), 2.4 (m, IH), 3.2 (m, IR), 3.6 (m, 2H), 3.72 (m, IH), 3.75 (d, IH), 4.4 (t, IH), 4.5 (m, 2H), 7.12 (m, 3H), 7.3 (d, IH), 7.42 (m, 2H), 7.5 (s, IH), 7.9 5 (s, 4H) LC-MS (ra/z) 463 (MH^; RT=2.2 (UV,ELSD): 90%, 100% 'H NMR (500 MHz, DMSO) 5d (S)-l-{2-[2~(3'FluorO'phenyisulfanyl)'5'thiophen-3-yl'phenoxy]-ethyl}- pyrrolidine'2-carboxylic acid hydrochloride froml-{2-[5'Bromo-2'(3-fluorO'phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine'2' carhoxylic acid tert-butyl ester Yield: 330 mg, 62% over two steps 'HNMR (500 MHz, DMSO) 1.8 (m, IH), 1.95 (m, 2H), 2.35 (m, IH), 3.12 (m, IH), 3.55 (m, 2H), 3.7 (d, IH), 4,35 (m, IH), 4.5 (m, 2H), 6.92 (d, IH), 7.0 (d, IH), 7.05 (dd, IHl, 7,35-7.5 (m, 4H), ".68 (m,2H), S.06 (s, IH) LC-MS (ra/z) 444 (MH^); RT=2.45 (UV,ELSD) 93%, 100% St{S)-i-{2-[2-(3--Fliioro-phenyisulfanyl)-4-pynmidin-5'yl-phenoxy]-ethyl}-pyrrolidine-l-carboxylic acid hydrochloride from I--{2-[4-Bromo-2-(3-fluoro-pheiiylsulfanyl)'phe}wxy]-ethyl}-pyirolidine-2-carboxylic acid tert-buty! ester Yield : 251 mg, 57% over two steps ^H NMR (500 MHz, DMSO) 1.8 (m, IH), 1.9-2.0 (m, 2H), 2.4 (m, IH), 3.1 (m, IH), 3,5 (m, 2H), 3,7 (m, IH), 4.4 (m, IH), 4.5 (d, 2H), 7, 05 (m, 3H), 7,35 (m, 2H), 7.8 (s, IH) LC-MS (iTi/z) 439.971 (MH^; RT-1.78 (UV,ELSD) 98%, 99% ?if{S)-l-{2-[3-(3-Fluoro-phenylsulfanyl)'3-methanesulfonyl-biphenyl'4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid hydrochloride fi-om l-{2-[4-Bromo-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyiTolidine-2-carboxylic acid butyl ester Yield 390 mg, 61% over two steps ^H NMR (500 MHz, DMSO) 1.8 (m, IH), 1.9 (m, 2H), 2.4 (m, IH), 3.2 (d, lH),3-25 (s, 3H), 3.6 (m, 2H), 3.72 (d, IH), 4.35 (t, IH), 4.4 (m, IH), 7.05 (m, 3H), 7.38 (m, 2H), 7.73 (dd, IH), 7,82 (s, IB), 7.85 (41H), 7.96 (d, IH), 8,12 (s, IH) LC-MS (m/z) 515.9410 (MH^; RT=2.05 (UV/ELSD) 94%, 94% Example 6 6a (S)-l-{2-[2-(3-Fluoro-phenylsu}fanyl)-4-morpholin-4-yl--phenoxy]-ethyl}' pyrrolidine-2-carboxylic acid hydrochloTide 1 - {2-[4-BroiTio-2-(3-fiuorO'phenylsulfanyl)-phenoxy]-ethyl] -p>TroUdine-2(S)~ carboxylic acid tert-buti'l ester (497 mg, 1.0 mmol) was dissolved in dry tetrahydrofuran (1 niL). Then palladium(II)dibenzyhdne acetone (Pd2dba3) (15 mg, 0.016 mmoi, 2-(di-tertbup|dphosphino)biphenylphosphine (21 mg, 0,07 mmol) and potassium EerZ-butoxide (159 mg, 1.42 mmol) were added to the vessel placed under an argon atmosphere. Morpholine (0.11 mL, 1.26 mmol) was added to the mixture which was then stirred overnight. The mixture was then diluted with ethyl acetate (25 mL), filtered and then evaporated to dryness. The residue was taken up in acetic acid (10 mL) and IM HCl/AcOH (10 mL) was added. The solution was stirred at room temperature for 16 hours before being evaporated to dryness. The cmde product was then purified by preparative LC-MS. The purified compound was dissolved in acetic acid (30 mL) annd IM HCL/AcOH was added (10 mL). The solvent was removed in vB-cuo and after reevaporation from dichloromethane the title compound was isolated as a colourless foam. Yield: 162 mg, 3A% OYST tivo steps. 'H NMR (500 MHz, DMSO) 1,8 (m,lH), 1.9-2.0 (m, 2H), 2.4 (m, IH), 3.1 (m,lH), 3.2 (br s, 4H), 3.5 (m, 2H), 3.7 (d, IH), 3,83 (m, 4H), 4.4 (m, 3H), 6.97 (d, IH), 7.0 (d,lH), 7.08 (dd, IH), 7.2 (d, IH), 7.33 (m, 3H) LC-MS (m/z) 447.5 (MH^t; RT=1.76 (UV/ELSD)=99.8%, 96.4% 6h(S)-l-{2-f2~(3-Fluoro-phenylsulfanyl)-4-piperidin'l-yl-phenoxyJ-ethyl}-pyirolidine-2-carboxylic acid hydrochlonde (S)-l-{2-[4-Bromo-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid tert-butyl esier (990 mg, 1.99 mmol) was dissolved in toluene (4 mL). To the solution was palladium(n)tris(dibenzylidneacetone) (Pdadbas), sodium ten-butoxide (270 mg, 2.SI mn:oI) and 2-(dicyclohexylphosphino)biphenyl (15 mg, 0.043 mmol) under an inert atmosphere. To the mixture was added piperidine (0.24 mL, 2.43 mmol) and the mixmre was heated to 80 "C for 15 hours. The mixtiire was allowed to cool to room temperamre. The mixture was then diluted with diethyl ether (35 mL) filtered and evaporated to dryness.The residue was then dissolved in ethyl acetate/diethyl ether, silica gel was added and the solvent removed in vacuo. The product absorbed on to silica gel was then placed on a sihca cartridge and then eluted with heptane/ (heptane:ethyl acetate:trietliylamine) 70/30 to 50/50. The intermediate butyl ester was isolated from relevant fractions (244 mg,0.487 mmol) and then dissolved in acetic acid (10 mL). To the solution was added IM HCl/AcOH (10 mL) and the solution was stirred for 16 hours. The title compound was isolated after evaporation to dryness. Yield: 301mg, 32% over two steps LC-MS (m/z) 445.0908 (Mlt); RT-1.44 (UV/ELSD)=S8%, 98% Pharmacological testing The compounds of the invention were tested in a well-recognised and reliable test measuring glycine uptalce: [^H]-Glycine uptake Cells transfected with the human GlyT-lb were seeded in 96 well plates. Prior to the experiment the cells wore washed twice m HBS (10 mM Hepes-tris (pH 7,4), 2,5 mM KCl, 1 noM C&Ch, 2,5 mM MgS04,) and pre-incubated with test compound for 6 minutes. Afterwards, 10 nM ^H-glycine was added to each well and the incubation was continued for 15 minutes. The cells were washed twice in HBS. Scintillation fluid was added and the Plates were counted on a Trilux (Wallac) scintillation counter. The test results showed, that the prepared compounds of the invention all showed inhibition below 10000 nM as IC50 in the above-mentioned assay. The compounds of the im-ention were also tested in a well-recognised and reliable microdialysis test. Method Male Sprague-Dawley rats, initially weighing 275 - 350 g, were used. The animals were housed under a 12-lir light/dark cycle under controlled conditions for regular in¬door temperature (21±2°C) and humidity (55±5%) with food and tap water available ad libitum. Rats were anaesthetized with hypnorm/donnicimi (2ml/kg) and intracerebral guide carmulas (CMA'12) were stereotaxically implanted into the brain positioning tiie dialysis probe tip in the ventral hippocampus (co-ordinates 5.6 mm posterior to bregma, lateral -5.0 mm, 7.0 mm ventral to dura). The rats were allowed to recover from surgeiy for at least 2 days. On the day of the experiment, a microdialysis probe (CMA/12, 0.5 mm diameter, 3 mm length) was inserted through the guide cannula. The probes were connected via a dual channel swivel to a microinjection pump. Perfasion of the microdialysis probe with filtered Ringer solution (145 mM NaCl, 3 mM KCl, 1 mM MgCl2, 1.2 mM CaCli) was begun shortly before insertion of tlie probe into tlie brain and continued for the duration of the experiment at a constant flow of 1 )il/min. After 165 min of stabiUzation, the experiments were initiated. A 20 or 40 min sampling regime was used throughout the experimental period. Time points were corrected for lag time of the perfusate from the microdialysis site to the probe outlet. After the experiments, the rats were sacrificed by decapitation. The brains were removed, frozen and sectioned (20 |im), and the position of the probes was verified. Analysis of glycine in the dialysates The concentration of glycine in the dialysates was analyzed by means of HPLC with fluorescence detection after precolumn online derivatisation with o-phatalaldehyde. The system consisted of a Hypersil AA-ODS column (5 ^m, 2.1 x 200 ram, Agilent) with a Agilent 1100 fluoresence detector (excitation, 266-340 nm; emission, 305-340 nm). Mobile phases consisted of A: 20 mM sodium acetate, 0.018% triethylamine, 0.3 % tetrahydrofuran, pH 7.2, B: 20 mM sodium acetate, 40% acetonitriie and 40% methanol pH 7.2. The ovsn temperature was set at 40 °C and flow rate was 0.45 mL/min. Data were collected and analysed using ChemStation software (Agilent) after calibration witli a range of standard glycine solutions (0.1 -10 )iM). Data presentation The mean value of 3 consecutive glycine samples immediately preceding compound administration served as the basal level for each experiment and data were converted to percentage of basal (mean basal pre-injection values normalized to 100%), wherein X is O, S or CR' 'R'^ wherein R' ' and R'^ independently are selected from H or C,.6 alkyl; Y is O or S; R', R^ R^ and R" are independently selected from hydrogen; halogen; cyano; nitre; Ci.6-alk(en/yn)yl; Ci_6-alk(en/yn)yIoxy; Ci.6-alk(en/yn)ylsulfanyl; hydroxy; hydroxy-C|.6-alk(en/yn)yl; halo-C|.6-alk{en/yn)yl; halo-Ci.6- alk(en/yn)yloxy; C3.a-cycloa]k(en)yl; C3.8-cycloalk(en)yl-Ci.6-alk{en/yn)yl; acyl; Ci.6-aIk(en/yn)yloxycarbonyl; C|.6-aIk(en/yn)ylsuIfonyl; aryl optionally substituted with a halogen, cyano, nitro, C|,6-alk{enyyn)yl, Ci_6- alk(en/yn)yloxy, C|.6-alk(en/yn)yisulfanyl, hydroxy, hydroxy-Ci.6-alk(en/yn)yl, halo-Ci.6-alk(en/yn)yl, halo-C|.6-alk(en/yn)yloxy, C3.g'Cycloalk(en)yl, C3.8- cycloalk(en)yl-C|.6-alk(en/yn)yl, acyl, C].6-alk(en/yn)yloxycarbonyl or C1.6- alk(en/yn)ylsulfonyl; monocyclic heteroaryl optionally substituted with a halogen, cyano, nitro, C|.6-alk(en/yn)yl, Ci_6-alk(en/yn)yloxy, C,.6- alk(en/yn)ylsulfanyl, hydroxy, hydroxy-Ci.6-alk(en/yn)yl, halo-Ci,&- alk(en/yn)yl, halo-Ci.6-alk(en/yn)yloxy, C3-rcycloalk(en)yl, €3,8- cycloalk(en)yl-C|.6-alk(en/yn)yl, acyl, C|.6-alk(en/yn)yloxycarbonyl or Ci,6-alk(en/yn)ylsulfonyl; or -NR'^R'^ wherein R'^ and R'"* independently are selected from hydrogen, C,.fi-alk(en/yn)yl, C3.a-cycloalk(en}yl, C3.8-cycloalk(en)yl-C|.6 alk(en/yn)yl or aryl, or R'^ and R'" together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N; R^ is aryl or monocyclic heteroaryl, optionally substituted with a halogen, cyano, nitro, Ci.6-alk(en/yn)yl, C|_^-alk(en/yn)yloxy, C|.6-a]k(en/yn}ylsulfanyl, hydroxy, hydroxy-Ci-6-alk{en/yn)yI, halo-C,.6-alk(en/yn)yl, halo-C|.6-alk(en/yn)yloxy, C3.g-cycloalk{en)yl, C3.8-cycioalk(en)yl-Ci.6-aIk(en/yn)yl, acyl, C|.6-alk(en/yn)yloxycarbonyl, C|.6-aIk(en/yn)ylsulfonyl or -NR'^R'^ wherein R'^ and R'^ independently are selected from hydrogen, Cj.6-alk(enyyn)yl, C3.8-cycloalk(en)yl, C3.8-cycloalk(en)yl-C|.6 alk(en/yn)yl or aryl, or R'^ and R'* together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from 0, S or N; R^ is selected from H, C|.6-alk(en/yn)yl, C|_6-alk(en/yn)yloxy, C,,6-alk(en/yn)ylsulfanyl or C3-8-cycloalk(en)yl, provided that when R^ is selected from C|_6-alk(en/yn)yloxy, or C,.6-alk(en/yn)ylsulfanyl then X is CR"R'^ wherein R" and R'^ independently are selected from H or C|.6 alkyl; R' and R^ are independently selected from H, C|.6-alk(en/yn)yl or C3.8-cycloalk(en)yl; R^ and R^ are independently selected from H, Ci.6-alk(en/yn)yl, hydroxy-C,.6-alk(en/yn)yl, C,.f, alk(en/yn)ylsulfanyl-Ci.6-alk(en/yn)yl or C3,g-cycloalk(en)yl; or / ft R and R together with the nitrogen form a saturated 3-7 membered heterocyclic ring, and R' is selected from H, C[.6-alk(en/yn)yi or Ca-a-cycloalk(en)yl, and R^ and R^ are independently selected from H, Cu^-alk(en/yn)yl, hydroxy-C!.6-alk(en/yn)yU Ci.,, alk(en/yn)ylsulfanyl-Ci.6-alk(en/yn)yl or C3.8-cycloalk(en)yl; or R and R together with the nitrogen form a saturated 3-7 membered heterocyclic ring, and R^ is selected from H, C].6-alk(en/yn)yl, C|_6-alk(en/yn)yloxy, C|.6-alk(en/yn)ylsulfanyl or C3.8-cycloalk(en)yi, provided that when R^ is selected from Ci_6-alk(en/yn)yloxy or C|.6-alk(en/yn)ylsulfanyl then X is CR"R'^ wherein R" and R'^ independently are selected from H or C|.6 alkyl, and R' and R^ are independently selected from H, C[,6-alk(en/yn)yl, hydroxy-Ci.6-aIk(en/yn)yK Cu R* and R^ together with the nitrogen form a saturated 3-7 membered heterocyclic ring, and R^ is selected from H, C].6-alk(en/yn)yl, C,_6-alk(en/yn)yloxy, C|.6-alk(en/yn)ylsulfanyl or C3.s-cycloalk(en)yl, provided that when R^ is selected from Ci_6-alk(en/yn)yioxy or Ci.6-alk(en/yn)ylsulfanyl then X is CR"R'^ wherein R" and R'^ independently are selected from H or Cj-c alkyl, and R' is selected from H, C|.6-alk(en/yn)yl or C3.g-cycloalk(en)yl, and R^" is selected from H, Ci.6-alk(en/yn)yl, hydroxy-Ci-6-aIk(en/yn)yi, Ci.^ alk(en/yn)ylsulfanyl-Ci.6-alk(en/yn)yl or C3.8-cycloalk(en)yl; R"* is H, Ci.6-alk(en/yn)yl, aryl, aryl-Ci.6-alk{enyyn)yl, wherein aryl is optionally substituted with a halogen, CF3, OCF3, CN, NO2 or C1.6-alk(en/yn)yl; or an alkali metal; or a sah thereof, such as a pharmaceutically acceptable salt. 2. The compound as claimed in claim I wherein X is selected from 0 or CHi. 3. The compound as claimed in any one of claims 1 to 2 wherein Y is O. 4. The compound as claimed in any one of claims I to 2 wherein Y is S. 5. The compound as claimed in any one of the preceding claims wherein R' is selected from hydrogen, C|,6-alkyl, halogen, phenyl, or phenyl substituted with one or two subtituents selected from Ci.6-alkyl or C,.6-alkoxy. 6. The compound as claimed in any one of the preceeding claims wherein R^ is selected from hydrogen; cyano; Cj.e-alkyl; halogen; phenyl; phenyl substituted with one or two subtituents selected from cyano, C|,6-alkyl, C|.6-alkoxy, or Ci.6-alkylsulfonyl; -NR'^R'' wherein R'^ and R'" together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N, such as morpholinyl, or piperidinyl; or monocyclic heteroaryl. such as pyrimidinyl. 7. The compound as claimed in any one of the preceeding claims wherein R is selected from hydrogen; Ci.g-alkyl; halogen; phenyl; phenyl substituted with one or two subtituents selected from cyano, C|.6-alkyl, or C|.6-alkoxy; or monocyclic heteroaryl, such as thiophenyl. 8. The compound as claimed in any one of the preceeding claims wherein R is selected from hydrogen, C|.6-alkyl, halogen, phenyl or phenyl substituted with one or two subtituents selected from C|.6-alkyl or C[.6-alkoxy. 9. The compound as claimed in any one of the preceeding claims wherein R^ is phenyl, optionally substituted with a halogen, C,.6-alkyi, Ci_«-alkyloxy, €,.6-alkylsulfanyl, halo-C,.6-alkyl. 10. The compound as claimed in any one of the preceeding claims wherein R^ is selected from H or Ci,6-a!kyl. 11. The compound as claimed in any one of the preceeding claims wherein R' is selected from H or Ci,6-alkyl. 12. The compound as claimed in any one of the preceding claims wherein R^ is selected from H, C].6-alkyl or C3.8-cycloalkyl. 13. The compound as claimed in any one of the preceding claims wherein R and R^ are independently selected from H or C|.6-alkyl. 14. The compound as claimed in any one of the preceding claims wherein R is H. 15. The compound as claimed in any one of claims 1 to 9 or 14 wherein R and R together with the nitrogen form a 1-pyrrolidinyI, l-piperidinyl or 1-azepinyl, optionally substituted with a C|,6-alkyl, and R' is selected from H, Ci.6-alk(en/yn)yl or C3.8-cycloalk(en)yl, and R^ and R^" are independently selected from H, Ci.6-alk(en/yn)yl, hydroxy-C,.6-alk{en/yn)yl, C,.^ alk(en/yn)ylsulfanyl-C|.6-alk(en/yn)yl or C3.g-cycloalk(en)yl. 16. The compound as claimed in any one of claims 1 to 9 or 14 wherein R and R together with the nitrogen form a 1-pyrroIidinyl, l-piperidinyl or 1-azepinyl, optionally substituted with a C|.6-alkyl, and R^ is selected from H, C|.6-alk(en/yn)yl, C,_6-alk(en/yn)yloxy, C!.6-alk(en/yn)ylsulfanyl or C3.8- cycloalk(en)yI, provided that when R^ is selected from Ci_6-alk(en/yn)yloxy or Ci.6-alk(en/yn)ylsulfanyl then X is CR"R'^ wherein R" and R'^ independently are selected from H or Ci.6 alkyl, and R^ and R^^ are independently selected from H, Ci.6-alk(en/yn)yl, hydroxy-C|.6-alk(en/yn)yI, C|.6 alk(en/yn)ylsulfanyl-Ci.6-alk(en/yn)yl or C3.8-cycloalk(en)yl. 17. The compound as claimed in any one of claims 1 to 9 or 14 wherein R^ and R^ together with the nitrogen form a l-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a Ci.g-alkyl, and R^ is selected from H, C|.6-alk(en/yn)yl, Ci^-alk(en/yn)yloxy, Ci^-alk(en/yn)ylsulfanyl or C3,8-cycloalk(en)yl, provided that when R^ is selected from C|_fi-3lk(en/yn)yloxy or Ci,6-alk(en/yn)ylsulfanyl then X is CR"R'^ wherein R" and R'^ independently are selected from H or Ci-e alky!, and R"" is selected from H, Ci.6-aik(en/yn)yl or C3.g-cycloalk(en)yl, and R^ is selected from H, C|.6-alk(en/yn)yl, hydroxy-Cus-alk(en/yn)yl, C|.6 alk(en/yn)ylsulfanyi-C|.6-alk(en/yn)yl or C3-8-cycloalk(en)yl. 18. The compound as claimed in claim 1 selected from (S)-l-(2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrroIidine-2- carboxylic acid. (S)-l-{2-[2-(4-lert-Bmyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrroIidine-2- carboxylic acid, (S)-l-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid, (S)- l-(2-[2-(3-Fluoro-phenylsulfanyl)~phenoxy]-ethyl}-pyrrolidine-2- carboxyiic acid, (S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid. (S)-l-{2-[2-(3-Chloro-phenyls[ilfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid, (S)-l-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrroiidine-2- carboxylic acid, (S)-l-{2-[2-(3-Chloro-4-fluoro-phenyIsulfanyl)-phenoxy]-ethyI}-pyrrolidine-2- carboxylic acid, (S)-l-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrroiidine-2-carboxylicacid, (S)-l-{2-[2-(4-Chioro-phenoxy)-pIienoxy]-ethyl}-pyrroUdine-2-carboxylicacid, (S)-l-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyr}-pyrroIidine-2-carboxylic acid, (S)-l-(2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxyiic acid, l-{2(R/S)-[2-(4-ChIoro-phenoxy)-phenoxy]-propyl}-pyrroIidine-2(S)- carboxylic acid, l-{2(RyS)-[2-(3,4-Ditluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)- carboxylic acid, (S)-l-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrroiidine-2-carboxylicacid, l-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)- carboxylic acid, l-{2(RyS)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl)-pyrrolidine-2(S)- carboxylic acid, l-{2(R/S)-[2-(3-ChIoro-phenylsuIfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)- carboxylic acid, ({2-[2-(4-tert-Butyl-phenylsulfanyi)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid, 2-{3-[2-(4-tert-ButyI-phenylsulfanyl)-phenoxy]-pyn"olidin-l-yl}-propionic acid. ((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N"methyl-amino)-acetic acid, ({2-[2-(3-Chloro-4-f]uoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)- acetic acid, {2-[2-(4-tert-Butyl-phenylsuIfanyI)-phenoxymethyl]-piperidin-l-yl}-acetic acid, ({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid, {4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-l-yl}-acetic acid, (N-2-propyl-{2-[2-(4-trif]uoromethyl-phenylsulfanyl)-phenoxy]-ethyI}-amino)- acetic acid, ({2-[2-(3,4-Dich!oro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid, (N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl)-amino)- acetic acid, 2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-I-yl}-propionic acid, (S)-(3-[2-(4-tert-Butyl-phenylsuIfany[)-phenoxy]-pyrrolidin-l-yl}-aceticacid, {{2-[2-(3-Chloro-4-fluoro-phenyIsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)- acetic acid, (N-2-propyl-(2-[2-{4-methylsuIfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)- acetic acid, {3-[2-(4-terl'Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl)-acelic acid, ((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-aceticacid, ({2-[2-{4-Chloro-phenylsulfanyl)-phenoxy]-ethyI-}N-methyl-amino)-acetic acid, (4-[2-(3,4-Dichloro-phenylsulfanyI)-phenoxy]-piperidin-l-yl}-aceticacid, 2-{3-[2-(4-Trifluoromethyl-phenyIsulfanyl)-phenoxy]-pyrro]idin-l-yl}- propionic acid, C(2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid ({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxyJ-ethyl}-N-methy!-amino)-acetic acid, {2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenoxymethyl]-piperidin-l-yl}- acetic acid, ({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid, (N-Methyl-{2-[2-(4-trifluoromethyi-phenylsulfanyl)-phenoxy]-ethyl}'amino)- acetic acid, 2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl}-propionic acid, 2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl}-propionic acid, 2-[3(R)-(2-(4-melhylphenyl)-sulfanyl-phenoxy)-pyrrolidin-l-yl]-propionicacid, {3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl}-acetic acid, 2-{3(R)-[2-(4-Trifluoromethyl-plienylsulfanyl)-phenoxy]-pyrrolidin-l-yl}- propionic acid, 2-{3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-l-yl}-propionic acid, ((l-[2-(3-Chloro-phenylsulfanyl)-phenoxymethyI]-propyl}-N-ethyl-amino)- acetic acid, ({l-[2-(3,4-Dichloro-phenylsu[fanyl)-phenoxy)-butan-2-yl}-N-ethyl-amino)- acetic acid. ({l-[2-(3,4-Dich!oro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-ammo)-acetic acid, ({l-[2-{3-Chloro-4-tluoro-phenylsulfanyl)-phenoxy]'butan-2-yl}-N-ethyl-amino)-acetic acid, ({l-[l-(3-Chloro-phenylsuIfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid, ((l-[2-(3-Chloro-4-tluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl'2-yl)}-N-ethyl-amino)-acetic acid, ({l-[2-(3-Chloro-4-fluoro-phenyisulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid, (S)-{l-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl }-N-metiiyI-amino)-acetic acid, (S)-((l-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl)-N-ethyl-amino)-acetic acid, ({l-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid, ({l-[2-(4-ChIoro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid, ((l-[2-(3-Chloro-phenylsulfanyl)-phenoxymethyl]-propyI}-N-methyl-amino)-acetic acid, {{l-[2-(4-Chloro-phenylsulfanyl)-phenoxymethyl]-propyl}-N-ethyl-amino)-acetic acid, (N-Ethyl-(l-[2-(3-fIuoro-phenylsulfanyI)-phenoxymetiiyl]-propyl}-amino)-acetic acid, (R)-({2-[2-(3,4-Dichloro-phenylsuIfanyl)-phenoxy]-l-metliyl-ethyl}-N-ethyl-amino)-acetic acid, (S)-(2{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-aceticacid, (R)-(2(2-[2-(3-Chloro-phenylsulfanyl)-pheiioxyM-propyl-N-methy!-amino)- acetic acid, ({2-[2-(3-FluorO'phenylsulfanyl)-phenoxy]-propyl}-N-methyl-aniino)-acetic acid, ({2-[2-(3-Chloro-phenylsuIfanyl)-phenoxy]-propan-lyI}-N-ethy]-amino)-acetic acid, ((l-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl- amino)-acetic acid, ({3-methyl-l-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}-N- ethyl-amino)-acetic acid, ({l-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-methyl- amino)-acetic acid, {S)-(l{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}N- methyl-amino}-acetic acid, (S)-(2-(2-[2-(3-FluorO'phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)- acetic acid, ({l-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-ethyl- amino)-acetic acid, (S)-({l-[2-(3,4-DichIoro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl- aniino)-acetic acid, ({l-[2-(3-Chloro-4-fluoro-plienyisulfanyI)-phenoxy]-3-methyl-butan-2-yl)-N- methyl-amino)-acetic acid, {{l-[2-(4-lerl-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl)-N-ethyl- amino)-acetic acid» ({2-[2-(3-Chloro-4-fiuoro-phenylsulfanyl)-phenoxy]-propan'l-yl}-N-ethyl- amino)-acetic acid, ({2-[2-(4-methoxy-ph6nylsulfanyl)-phenoxy]-propan-l-yl}-N-CycIohexyl- amino)-acetic acid, { [2-(2-(4-methylsulfanyl-phenoxy)-propan-l-yl-]-N-cyclohexyl-amino}-acetic acid, ({2-[2-(3-ChIoro-phenylsulfanyl)-phenoxy]-propan-l-yl}-N-cyclohexyl- amino)-acetic acid, (S)-l-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrroIidine-2- carboxylic acid, {S)-2-({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl- amino)-propionic acid, ({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)- acetic acid, (S)-l-(2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pytTolidine-2- carboxylic acid, (S)-l-{2-[3-ChIoro-2-(3-fluoro-phenylsulfunyl)-phenoxy]-ethyl}pyrroIidine-2- carboxylic acid, (S)-l-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrToUdine-2- carboxylic acid, (S)-l-{2-[4-Cyano-2'(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2- carboxylic acid (S)-l-[2-(5-Chloro-2'phenylsulfanyl-phenoxy)-ethyI]pyrrolidine-2-carboxylic acid, (S)-l-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yioxy]-ethyI}-pyrroIidine-2- carboxylic acid, (S)-{2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}- pynolidine-2-carboxylic acid. {S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}- pyrrolidine-2-carboxylic acid, (S)-l-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyI)-biphenyl-3-yloxy]-ethyI}- pyrrolidine-2-carboxylic acid, (S>!-{2-[2-(3-Fluoro-phenylsu!fanylV5-thiophen-3-y!-phenoxy]-ethyl}- pyrrolidine-2-carboxylic acid, (S)-l-{2-[2-(3-FIuoro-phenylsutfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}- pyrrolidine-2-carboxylic acid, (S)-l-{2-[3-(3-Fluoro-phenylsulfanyI)-3-methanesulfonyl-biphenyl-4'yloxy]- ethyl}-pyrrolidine-2(S)-carboxylicacid, (S)-l-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpliolin-4-yl-phenoxy]-ethyl}- pyrrolidine-2-carboxylic acid, (S)-l-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-l-yl-phenoxy]-ethyl}- pyrrolidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

Documents:

2812-chenp-2005 abstract-duplicate.pdf

2812-chenp-2005 abstract.pdf

2812-chenp-2005 claims-duplicate.pdf

2812-chenp-2005 claims.pdf

2812-chenp-2005 correspondence-others.pdf

2812-chenp-2005 correspondence-po.pdf

2812-chenp-2005 description (complete)-duplicate.pdf

2812-chenp-2005 description (complete).pdf

2812-chenp-2005 form-1.pdf

2812-chenp-2005 form-18.pdf

2812-chenp-2005 form-26.pdf

2812-chenp-2005 form-3.pdf

2812-chenp-2005 form-5.pdf

2812-chenp-2005 pct search report.pdf

2812-chenp-2005 pct.pdf

2812-chenp-2005 petition.pdf